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The small Rab GTPase, Rab22B, was first cloned in 1996 (Chen et al., 1996). 
However, other than the fact that it is brain-enriched, its’ brain expression profile, exact 
cellular and sub-cellular localization, and functions have remained uncharacterized. 
Specific antibodies against Rab22B, which does not cross react with its close paralogue 
Rab22A, were generated to help to answer the above questions. 
 
A tissue survey using specific antibodies against Rab22B confirms that Rab22B is 
indeed brain-enriched, but is also expressed in appreciable levels in the spleen and 
intestine. Immunohistochemistry analysis revealed that in the mouse embryonic brain, 
Rab22B labeling is found in nestin and RC2 epitope-positive fibers of the radial glia. In 
the mouse adult brain, Rab22B is rather specifically expressed in glial fibrillary acidic 
protein (GFAP)-positive astrocytes, but apparently undetectable in III tubulin (TuJ)-
positive neurons and CNPase-positive oligodendrocytes. These observations were further 
confirmed with the staining of glia cells in culture. 
 
Detailed immunocytochemistry analysis revealed that the primary membrane 
localization of Rab22B is at the trans-Golgi network (TGN). Over-expression of the 
GTP-binding mutant Rab22B S20N disrupted the TGN localization of a dynamic marker, 
TGN46, which cycles between the TGN and the plasma membrane. Other TGN resident 
membrane protein such as syntaxin 16, and cis-Golgi markers such as GM130 and 
syntaxin 5, and the TGN/late endosome marker mannose 6-phosphate receptor (M6PR), 
are however not affected. These results demonstrate that the effect of Rab22B SN on 
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TGN traffic disruption affects a dynamic TGN marker rather than the more static 
residents.  
 
Rab22B’s apparent TGN localization and the ability to disrupt a specific marker 
seemed to indicate that it may be involved in trafficking in and/or out of the TGN. 
Further investigations illustrate that Rab22B is not involved in retrograde trafficking of 
some common endocytic cargoes such as transferrin and Shiga B toxin. However, over-
expression of Rab22B S20N mutant inhibits the exit of the anterograde cargo vesicular 
stomatitis G protein (VSVG) out of the TGN  
 
Recent reports had also revealed that Rab22B shares its guanine nucleotide 
exchange factor, GAPex-5, with Rab5 (Lodhi et al., 2007). The silencing of GAPex-5 
appears to mediate the trafficking of EGFR. In spite of being non-essential for 
endocytosis for some common cargoes, Rab22B appears to mediate EGFR trafficking. 
Rab22B silencing inhibited or delayed the trafficking of EGFR, as well as Texas-Red 
conjugated EGF, into the CD63-positive late endosomal/lysosomal compartment. 
Affinity pull-down assay and co-immunoprecipitation analysis show that Rab22B 
interacts with EGFR in a GTP-dependent manner.  
 
While the silencing of Rab22B does not affect the phosphorylation kinetics of the 
signaling intermediates downstream of EGFR, ERK1/2, dephosphorylation of ERK1/2 
appears to be slower. This may also shed light on why the proliferation rates, monitored 
Abstract 
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over 72 hours, were significantly increased in cells treated with Rab22B siRNA 
compared to scramble control RNA. 
 
In summary, my work revealed Rab22B as the first Rab GTPase that is 
specifically enriched in the brain astroglia lineage, and may play a role in regulating 
Golgi and post-Golgi trafficking. 
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1. Introduction  
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Fig. 1.1: Schematic diagram depicting the paths of membrane traffic within a typical 
eukaryotic cell.  trans-Golgi = TGN. 
 
 
The eukaryotic cell is characterized by an elaborate internal membrane system, 
which are connected by tightly regulated membrane traffic processes. Once newly 
synthesized secretory proteins are translocated into the endoplasmic reticulum (ER - 
brown) lumen, they can be packaged into anterograde transport vesicles. Some proteins, 
mainly ER-localized proteins, are retrieved from the cis-Golgi (Cis - yellow) back to the 




























proteins destined for the secretory pathway will move from the cis- to the trans- position 
of the Golgi apparatus. This process may be mediated by transport vesicles, or may occur 
by a cisternal membrane ‘maturation’ process known as cisternal progression (Elsner et 
al., 2003; Storrie, 2005). Proteins destined for the secretory pathway will eventually reach 
a complex network of membranes and vesicles termed the trans-Golgi network (TGN), 
which is a major sorting station in the secretory pathway (Gu et al., 2001). From this 
sorting station, a protein can be loaded into either one of the three different kinds of 
transport carriers.  
 
The first type of carrier (purple) constitutively moves and fuses with the plasma 
membrane to release the contents in it in a process known as constitutive secretion or 
exocytosis. Examples of proteins that are released constitutively are some extracellular 
matrix (ECM) by fibroblasts and serum proteins by hepatocytes. The second type of 
carrier (blue) is stored within the cell until a signal for exocytosis causes the release of 
the contents in it into the extracellular environment. Amongst the proteins released in this 
regulated manner are hormones from various endocrine cells and neurotransmitters from 
neurons. The third type of carrier (orange) generated from the TGN is directed to the 
lysosome via the late endosome. An example of protein that is delivered via this pathway 
is the lysosomal digestive enzymes.  
 
In the endocytic pathway, vesicles that bud off from the plasma membrane will 
fuse with the early endosome (pink vesicles). From the early endosome, some proteins 
are sorted to the lysosome (gray vesicle) via the late endosome (red vesicle) for 
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degradation or they can also be recycled back to the cell surface. Receptor-mediated 
endocytosis is a way for cells to take up nutrients, such as cholesterol in the form of 
lipoproteins. Receptor-mediated endocytosis of receptor-ligand complexes also functions 
in regulating cellular signaling (Derby and Gleeson, 2007; Hanyaloglu and von Zastrow, 
2008). 
 
1.1 An overview of Rab GTPases and membrane trafficking 
 
The enormous flux of membrane traffic within a cell at any point of its existence 
necessitates stringent control of both the rate and specificity of traffic flow. The small 
GTPase family of Rab proteins plays essential roles in various aspects of membrane 
traffic control. The Rabs are the largest subfamily of the Ras superfamily of small 
GTPases, with more than 60 members encoded by the human genome, and are localized 
to different subcellular compartments (Pereira-Leal and Seabra, 2001; Deneka et al., 2003; 
Pfeffer and Aivazian, 2004; Jordens et al., 2005). Through a GDP-GTP exchange cycle, 
Rabs function as molecular switches to mediate vesicular transport along the cytoskeleton 
by engaging specific motor proteins, ensuring efficient tethering and docking of vesicles 
to target membranes, and timing vesicle fusion with the engagement of soluble N-
ethylmaleimide sensitive factor (NSF) (Zhao et al., 2007) attachment receptor (SNARE) 
(Ungermann and Langosch, 2005; Hong, 2005) proteins. The exchange of GDP-GTP is 
modulated by three different classes of regulatory proteins, namely the guanine 
nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs) and guanine 
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nucleotide dissociation inhibitors (GDIs) (Fig. 1.2) (to be discussed in further details in 
Section 1.1.1). 
 
Fig. 1.2: Rab’s activities and functions is regulated by three classes of regulatory 
molecules, namely the guanine nucleotide exchange factor, the GTPase activating protein 
and guanine nucleotide dissociation inhibitor. Once Rab proteins are bound to a 
membrane of a vesicle via its lipid tail, the exchange of GDP to GTP is catalyzed by 
guanine nucleotide exchange factors. Rabs bound to GTP are in the active conformation 
and can now interact with its effectors on the vesicle’s membrane. Binding of Rab to a 
Rab effector will help to tether the vesicle to its appropriate target membrane and allows 
other membrane surface proteins such as SNAREs to interact, resulting in the docking of 
the vesicle to the target membrane. When the Rab has fulfilled its function, GTP is 
hydrolyzed back to GDP. Rabs have low intrinsic GTPase activity, which is enhanced by 
the GTPase activating proteins. In the cytosol, the GDP dissociation inhibitor binds to the 
GDP-bound Rab and inhibits the exchange of GDP for GTP, which would reactivate the 
Rab protein. 
 
Bioinformatical analysis has revealed that Rab genes exhibit a rather strict 
phylogeny of homology and function. The Rab proteins found in Saccharomyces 
cerevisiae had be grouped into 10 major subclasses (Rab5, Rab7, Rab6, Rab4, Rab28, 
Rab38, Rab11, Rab1, Rab8 and Rab3) (Buvelot et al., 2006) of eukaryotic Rabs and can 
be subgrouped into eight branches in a phylogenetic tree, with members on the same 
branch exhibiting similar patterns of cellular localization and function (Pereira-Leal and 
Seabra, 2001). The roughly six fold increase in terms of the number of Rabs from the 
unicellular yeast to human is more than a simple reflection of an increase in cellular 
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membrane traffic complexity. It is conceivable that some Rabs, enriched in particular cell 
or tissue types, have evolved to performed specific functions. This cell or tissue type 
specialization of members of a protein family also occurs for the other components of the 
membrane traffic machinery, namely the coat proteins and SNAREs (Newman et al., 
1995; Wang and Tang., 2006). 
 
The Rab GTPases share a similar fold that contains the molecular elements require for 
guanine nucleotide binding and hydrolysis (Milburn et al., 1990; Schlichting et al., 1990) 
with Ras GTPases. This fold comprises of a six stranded -sheets, surrounded by five -
helices and is common to all small GTPases within the Ras superfamily. In Rab GTPases, 
this fold is also known as the Region I and II of the GTP-binding domains and similarly, 
mutant forms of Rabs can be generated by creating amino acid substitutions in the Region 
I (GDTGVDKS) and II (DXXGQ) of the GTP-binding domains. At Region I, substitution 
of the serine (S) residue to an asparagine (N) residue (to be refered as a SN mutant) will 
render the Rab protein deficient in binding of GTP, which means that it will be 
permanently bound to GDP. At Region II, substitution of the glutamine (Q) residue to a 
leucine (L) residue (to be refered as a QL mutant) will convert the Rab protein to a 
constitutively active Rab protein, rendering it permanently bound to GTP. 
 
1.1.1 Regulators of Rab GTPases 
 
Although Rab proteins are themselves homologous, the GEFs and GAPs are 
reasonably specific for a particular Rab protein or closely related Rab proteins, and these 
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share very little structural or sequence homology amongst each other. The roles of 
modulators of small GTPases have been extensively delineated for Ras and other 
subfamilies of the Ras superfamily, such as the Rho GTPases. Modulators of Rab 
GTPases’ activities have been identified, and will presumably play similar roles.  
 
GEFs for GTPase are a family of proteins that possess a tandem array of Dbl 
(diffuse B-cell lymphoma) homology and a pleckstrin homology (PH) domain at its C-
terminus (Eva and Aaronson, 1985). The Dbl and PH homology domains are largely 
responsible for the GEFs’ nucleotide exchange activity.  The GEFs serve as a positive 
regulator of GTPases by promoting GDP-GTP exchange. The binding of GEFs to 
GTPases causes a decrease in its affinity for guanine nucleotide. GEFs for the Rho family 
members have been extensively characterized. So far, more than 30 Rho-specific GEFs 
have been found. Some GEFs are specific to either Rho or Rac, e.g. p115 for Rho and 
Tiam-1 for Rac, while others can act on both Rho and Rac, e.g. Vav2 and Vav3 for both 
Rho and Rac. Recently another genetically distinct group of proteins have been found to 
be able to act as GEFs for Rho GTPases. These are members of the DOCK 180/CED-
5/myoblast city family which possess a “Docker” or dock homology region 2 (DHR-2) 
domain (Wu and Horvitz, 1998). They show GEF’s activity that is specific to Rac (Cote 
and Vouri, 2002). Furthermore, the Rac GEFs themselves are regulated by upstream 
kinases. Evidences have shown that members of the Vav, Sos, Tiam, PIX, SWAP-70 and 
P-Rex families of GEFs can be activated by PI3K (phosphoinositide-3-kinase) in vivo 




Rab GEFs are not as extensively documented, but a good number of them are now 
characterized. Similarly, the Rab GEFs also positively regulate Rab GTPases activity by 
promoting GDP-GTP exchange, with the binding of GEF to GTPase, thereby, causing a 
decrease in its affinity for GDP (Horiuchi et al., 1997; Gournier et al., 1998; Jones et al., 
2000; Lippe et al., 2001; Burton et al., 2004).  
 
Contrastingly, GAPs serve as negative regulators by increasing the intrinsic 
GTPase activity, and accelerates the conversion of GTP-bound Rabs to the inactive, 
GDP-bound state (Strom et al., 1993; Clabecq et al., 2000; Will and Galwitz, 2001; Haas 
et al., 2005; Sakane et al., 2006; Pan et al., 2006). The family of Rho GAPs possesses a 
conserved GAP domain (also known as BH domain) which is necessary and usually 
sufficient for the GAP activity (Zheng et al., 1993). So far 53 human Rho GAP domain-
containing proteins are identified (Peck et al., 2002). 
 
The GAPs for Rab GTPases have also been identified and characterized (Alberts 
et al., 1999; Pan et al., 2006). The TBC (Tre-2, Bud2 and Cdc16) domain had been 
identified as a crucial domain for providing the critical arginine residues, which 
determines the GAP’s in vivo and in vitro activity.  
 
The GDIs are also negative regulators of Rabs, and function by blocking GDP 
dissociation via interactions with the isoprenylated C-terminus tail of Rabs (Pfeffer and 
Aivazian, 2004; DerMardirossian and Bokoch, 2005). At steady state, the majority of Rab 
proteins are membrane bound. However, there is also a pool of cytosolic Rab proteins 
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and these cytosolic Rab proteins are bound to GDIs. GDIs can retrieve Rabs, in their 
GDP-conformation, from their fusion targets after vesicle fusion and assist in delivering 
Rab proteins to their specific membrane compartments to enable them to participate in 
specific trafficking processes (Pfeffer et al., 1995).  
 
1.1.2 Effectors of Rab GTPases 
 
Rab proteins functions through their interactions with an array of effector 
proteins (Groosshans et al., 2006). These include actin-dependent motor proteins (such as 
myosin Va, which is recruited by Rab27A to melanosomes via melanophilin (Strom et al., 
2002)), microtubule-dependent motor proteins (such as Rabkinesin-6, which interacts 
with Rab6 (Echard et al., 1998)), tethering complexes (such as that based on early 
endosomal antigen 1 (EEA1) (Christoforidis et al., 1999) or p115/GM130 (Allan et al., 
2000), as well as other regulatory complexes (such as RIM/Munc13/-liprins, which 
interacts with Rab3A to regulate synaptic vesicle exocytosis (Schoch et al., 2002)  Over 
the past few years, structural analysis have revealed that Rabs assume a similar general 
structure, but
 
have very distinctive effector binding surfaces that permit selective 
recognition
 
by diverse effector proteins. Interestingly, even highly conserved amino acid 
residues can contribute to
 
structural distinctions between Rabs (Pfeffer, 2005). 
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1.2 Rab GTPases in the central nervous system 
 
 
Fig. 1.3: A schematic diagram depicting the localization and function of Rab GTPases in 
diverse neuronal processes (polarized neurite outgrowth/regeneration, axonal retrograde 
transport, postsypnaptic glutamate receptor trafficking and synaptic vesicle exocytosis) 
(Ng and Tang, 2008).  
 
The mammalian brain is perhaps the most sophisticated organ ever to evolve 
within the animal kingdom. In the brain, specialized cell types performs multiple 
specialized functions that together support the brain’s central role in the organism’s 
sensory, motor and cognitive operations. Membrane traffic in each brain cell type would 
bear the basic machineries and activities of any ordinary cell, but would also have its own 







































To date, a number of Rabs, such as Rab3A, Rab8 and Rab23, have been shown 
to be brain-enriched and have documented roles in neurons (Geppert et al., 1997; Evans 
et al., 2003). Recent findings on the roles played by Rab GTPases, their regulatory 
modules and effectors in the central nervous system (CNS), will be briefly discussed and 
summarized below, with respect to anterograde and retrograde transport within the 
neuronal domains, CNS development and regulation of synaptic transmission.  Recent 
findings on Rab GTPases in glial cells will also be discussed. A detail understanding of 
how Rabs function in neurons and glia, particularly in concert with each other and other 
Ras superfamily members (Matozaki et al., 2000), is essential for better comprehension 
of multiple aspects of neuron and glia physiology and diseases’ pathophysiology.  
 
1.2.1 Rab GTPases in neuronal protein trafficking  
 
Neurons are polarized cells with distinct plasma membrane domains, namely the 
axonal and the somatodendritic domains. These domains are established upon terminal 
differentiation and morphological changes associated with polarized outgrowth of 
neurites can be re-established and analyzed in culture (Dotti et al., 1988). Polarized 
outgrowth of neurites, as one would expect, involves components of the vesicular traffic 
machinery such as SNAREs (Martinez-Arca et al., 2001) and tethering factors such as the 





Polarized neuronal trafficking 
 
Polarized membrane trafficking during neurite formation would involve not just 
anterograde exocytic transport from the TGN, but also membrane recycling from the 
endosomes. An important Rab protein that is involved in both these processes is Rab11. 
One primary function of Rab11 in non-neuronal cells is to control membrane
 
trafficking 
through the recycling endosomes. Dominant-negative
 
Rab11A appears to inhibit apical 
recycling and basolateral-to-apical transcytosis
 
in polarized Madin-Darby canine kidney 
(MDCK) cells (Wang et al., 2000). In the brain, Rab11 is localized to the somatodendritic 
domain of neurons (Sheehan et al., 1996). Mechanistic insights into Rab11’s role in 
neurite formation was provided through the discovery of protrudin, a protein with 
multiple functional domains, one of which is a Rab11 binding domain (RBD11) (Shirane 
and Nakayama, 2006). This domain allows protrudin to preferentially interact with GDP-
bound form of Rab11. The over-expression of protrudin promoted neurite formation in 
hippocampal neurons while the depletion of protrudin by RNA interference in PC12 cells 
inhibited NGF-induced neurite outgrowth, and resulted in membrane extension in all 
directions. In the absence of NGF, protrudin is diffused throughout the cell body. 
However, in the presence of NGF, protrudin concentrates at the perinuclear region 
colocalizing with Rab11, and using time-lapse video microscopy, protrudin could 
eventually be found in association with vesicles at the tips of growing neurites. 
Interestingly, over-expression of a constitutively active (Rab11-Q70L) mutant 
phenocopied the morphological effects of protrudin-silencing, while over-expression of 
GDP-bound Rab11-S25N resulted in changes similar to protrudin over-expression. 
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Protrudin also contains six potential extracellular signal-regulated kinase (ERK) 
phosphorylation sites, and two consensus ERK binding sites. Phosphorylation of 
protrudin by ERK in response to NGF treatment apparently promotes protrudin 
association with Rab11-GDP. Thus, the Rab11-protrudin interaction appears to be an 
important mechanism in regulating directional membrane trafficking required for neurite 
formation. 
 
The involvement of other Rabs in neurite formation has been shown but 
functional and molecular details have been lacking, as in the case of Rab2. The ER-Golgi 
boundary localized Rab2 has been shown to enhance neuronal adhesion as well as neurite 
growth when the bacterially expressed protein is introduced into cultured cells by 
trituration (Ayala et al., 1990) but the molecular mechanism behind this observation is 
still not known.  
 
 Neuronal domain-specific anterograde transport 
 
 Rab8 is essential in several aspects of polarized neuronal transport, a function that 
is in line with its wider roles in plasma membrane trafficking in other polarized cell types, 
such as epithelial cells (van Ijzendoorn et al., 2003). Rab8 is localized preferentially in 
the somatodendritic domain, and not the axon, as observed in hippocampal neurons. A 
role for Rab8 in dendrite-specific transport was demonstrated by examining the newly 
synthesized E2 glycoprotein in neurons infected by Semiliki forest virus (SFV-E2) 
(Huber et al., 1993). The introduction of Rab8 antisense oligonucleotides markedly 
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reduced the transport of SFV-E2 from the neuronal cell body to the dendrites, but had no 
effect on axonal transport of influenza haemaglutinin (HA). Furthermore, morphological 
maturation of primary hippocampal neurons in culture was also inhibited by Rab8 
depletion, while depletion of Rab3a (a neuronal specific Rab involved in synaptic vesicle 
exocytosis, see below) had no such effect (Huber et al., 1995). Differential interference 
contrast microscopy revealed that there was a dramatic reduction in the number of 
vesicles undergoing anterograde transport in Rab8-depleted cells and restriction in newly 
formed exocytic vesicles (labeled by Bodipy-ceramide) from moving into the neurites. 
These studies implied that Rab8 plays a role in regulating polarized neurite outgrowth. 
 
 The trafficking of rhodopsin to the rhabdomeres, a specialized compartment 
within the apical membrane surface of developing Drosophila embryo, had been a 
popular model for investigating trafficking in photoreceptor cells and this process 
involves a host of different Rab proteins (Deretic, 1997). During photoreceptor terminal 
differentiation, a massive flow of membrane traffic helps to deliver rhodopsin and other 
phototransduction proteins to an apical subdomain to form photosensory organelles, 
invertebrate rhabdomeres and vertebrate outer segments. The proper targeting of 
rhodopsin to this domain is crucial for normal development and, if impaired, leads to 
retinal degeneration. Besides playing a general role in neuronal traffic and neurite 
outgrowth, Rab8 and Rab11 also regulate polarized transport processes in these 




Early studies suggested that Rab6 (Shetty et al., 1998) and Rab8 associate with 
post-Golgi membranes sequentially at different stages during rhodopsin transport, and 
Rab8 may mediate the interaction of transport vesicles or membrane with actin filaments 
in rod outer segment disk morphogenesis (Deretic et al., 1995). In Xenopus, the 
expression of a dominant negative Rab8 caused rapid retinal degeneration. It was 
observed that in the surviving peripheral rod cells, one could see an accumulation of 
tubulo-vesicular structures at the base of the connecting cilium, indicating that the Rab8 
mutant induced a defect in vesicular docking or fusion to post-Golgi membranes in rod 
cells (Moritz et al., 2001).  
 
 Another Rab protein that has been implicated in rhodopsin transport is Rab11, 
which is essential for Drosophila eye development (Alone et al., 2005). In the larval stage, 
Rab11 is mainly expressed in the photoreceptor cells and upon reaching adulthood, it 
localizes to the rhabdomeres and lamina neuropil of the eyes. During development, 
rhodopsin traffics to the rhabdomeres, and rhodopsin could be found colocalizing with 
Rab11 in vesicles at the base of the rhabdomere. Depletion of Rab11 or the over-
expression of dominant-negative Rab11 mutants disrupts rhabdomere morphogenesis, 
resulting in the accumulation of rhodopsin-bearing vesicles in the cytosol (Satoh et al., 
2005).  
 
Other than rhodopsin, Rab11 is also required for the transport of the transient 
receptor potential (TRP) gene product, another rhabdomeric protein which is a light-
activated Ca
2+
 channel that serves phototransduction (Satoh et al., 2005; van de Graaf et 
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al., 2006). As Rab11 is also important for the formation of late endosomal multivesicular 
bodies in rhabdomeres, it is also expected to have a more general role in rhabdomeric 
membrane traffic.  
 
 Axonal retrograde transport 
 
 In neuronal cells, the family of Trk neurotrophins binds to their receptors and 
exerts important activities by promoting both survival and neurite outgrowth. Upon 
binding, the neurotrophin-receptor complexes are internalized into endosomal 
compartments. However, signaling activities essentially continue in these endocytic 
structures known as signaling endosome (Grimes et al., 1996; Ye et al., 2003). Activated 
TrkA can be found in both early endosomes and late endosomes/multivesicular bodies 
(Saxena et al., 2005). Signaling processes persist in these membranous structures as they 
travel via the dynein-based axonal retrograde transport pathway towards the cell body 
(Barker et al., 2002, Heerssen and Segal, 2002). As the endosomal Rab5 and Rab7 are 
known to localize to the early endosomes and late endosomes/multivesicular bodies, their 
roles in regulating the various stages of neuronal endocytosis and neurotrophin signaling 
had received much attention.  
 
 The importance of Rab7 in TrkA trafficking is illustrated by the fact that Rab7 
could be co-immunoprecipitated with TrkA (Saxena et al., 2005). When PC12 cells are 
over-expressed with dominant-negative Rab7 T22N, TrkA is accumulated in the 
endosomes, resulting in the prolonged signaling of internalized TrkA. This led to an 
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enhancement of TrkA signaling in PC12 cells exposed to a limited stimulation (a brief 10 
min pulse) by NGF, as assessed by phosphorylation of TrkA, ERK1/2 activation, neurite 
outgrowth, as well as the expression of regeneration marker GAP-43.  
 
While Rab7 is essential for long-range axonal retrograde transport, it is Rab5 that 
is required for early endocytosis of neurotrophins. This is illustrated by the fact that Rab5 
is absent from vesicles carrying the tetanus toxin heavy chain, TeNT HC undergoing 
retrograde axonal transport (Deinhardt et al., 2006). Accordingly, GFP-tagged Rab5 is 
found largely in TeNT HC-containing vesicles that exhibit oscillatory, short-range 
bidirectional movements, but not those undergoing long-range retrograde transports. The 
latter type of vesicles contains Rab7, and axonal transport of TeNT HC can be blocked by 
Rab7 N125I (a Asparagine to Isoleucine mutation, which will result in a mutant that is 
GTP-binding deficient) over-expression. The above findings have important clinical 
implications, as mutations of Rab7 are found in patients suffering from Charcot-Marie-
Tooth type 2B neuropathy (Verhoeven et al., 2003) and ulcero-mutilating neuropathy 
(Houlden et al., 2004). Rab7 dysfunction may therefore cause neurodegeneration by 
affecting the trafficking of neurotrophin receptors, and is a potential strategic target for 




1.2.2 Rab GTPases in CNS development 
 
Central nervous system development 
 
 As key regulators of membrane transport, Rabs GTPases are presumably 
important for developmental processes, which mandate the delivery of proteins to the 
right cellular locations with spatial and temporal accuracy. However, knowledge in the 
requirement of Rab GTPases during the development of the nervous system is scarce. 
Rab11 and Rab23 are one of the few Rab GTPases which are known to be involved in 
this tightly-regulated process.  
 
Rab11 is not only required for Drosophila eye development (Alone et al., 2005), 
it is also essential for Drosophila embryogenesis. Rab11 endosomes are important 
trafficking intermediates that control exocytosis and membrane growth during the process 
of cellularization in embryogenesis (Pelissier et al., 2003).  The interacting protein, 
Rab11 family-interacting protein 4 (Rab11-FIP4), is recently shown to be expressed 
predominantly in neural tissues, and is important for retinal development in both zebra 
fish (Muto et al., 2006) and mouse (Muto et al., 2007). 
 
 In the Drosophila nervous system, trafficking of Delta, the ligand of Notch, in 
sensory organ precursor cells derived from asymmetric cell division, is different in the 
two daughter cell types, named pIIa and pIIb (Emery et al., 2005). For pIIb, Delta 
traversed through the Rab11-containing recycling endosome. pIIa, however, appear to 
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lack recycling endosomes, apparently as a result of the failure by its centrosome to recruit 
the Rab11 binding partner Nuclear fallout (Nuf). This demonstrates that the recruitment 
of Nuf by Rab11 is essential for recycling endosome formation. The trafficking through 
recycling endosomes may also be essential for the signaling capacity of the mouse Delta 
homolog, Delta-like-1 (Dll1). 
 
The evolutionarily conserved and neuronally expressed Drosophila Beige and 
Chediak-Higashi (BEACH) domain protein, Blue cheese (Bchs), acts as an antagonist of 
Rab11 during development (Khodosh et al., 2006). The Bchs protein is associated with 
vesicles and colocalized extensively with Rab11 at the neuromuscular junction (NMJ). At 







 flies, suppressed bristle defects and it was also 
observed that there was an increase in synaptic bouton density and branching.  
 
 Rab23 is another Rab protein with a specific function during mammalian CNS 
development. Sonic hedgehog (Shh) functions as a morphogen at the early neural tube to 
specify the expression of ventral cell markers. open brain (opb) was first identified as a 
natural mouse mutation resulting in severe defects in the developing neural tube (Gunther 
et al., 1994). Phenotypically, the opb neural patterning defects appeared opposite to that 
resulting from a lost of shh. opb also appears to act downstream of shh signaling , as the 
shh phenotype is at least partially rescued in opb mutant background. For example, 
ventral cell types, including the floor plate, are absent in shh mutants, but are present in 
shh opb double mutants. Positional cloning revealed that opb encodes Rab23 
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(Eggenschwiler et al., 2001). However, the exact role of Rab23 in antagonizing shh 
signaling is unclear at the moment. Although it is conceivable that Rab23 may regulate 
the cellular dynamics of components of the Shh pathway, it does not appear to act 
directly on either its transmembrane receptor Patched1, or the downstream effector 
Smoothened (Wang et al., 2006). Recent findings indicate that several nonsense 
mutations of human Rab23 underlie the autosomal recessive disorder Carpenter’s 
syndrome (Jenkins et al., 2007), with patients exhibiting some developmental congenital 
deformities. Rab23 may also have a function in neurons beyond Shh signaling during 
development, as it is also expressed in abundance in adult neurons (Guo et al., 2006).  
 
1.2.3 Rab GTPases in the regulation of synaptic transmission 
 
 The Rab3 subfamily (Rab3A, Rab3B, Rab3C, and
 
Rab3D) is arguably the most 
extensively investigated Rabs in terms of synaptic function. The Rab3 proteins are 
expressed in brain as well as endocrine tissues and, in conjunction with their effectors 
such as rabphilin (Shirataki et al., 1993; Li et al., 1994) and Rim (Wang et al., 1997), 
function in regulated exocytosis and neurotransmitter release (Geppert et al., 1994; 
Darchen and Goud, 2000). The reported function of Rab3 proteins in exocytosis have 
ranged from docking (Martelli et al., 2000) and fusion (Geppert et al., 1997; Schluter et 
al., 2002) to vesicle recycling, and some of the findings are at variance with each other 




Surprisingly, the knock-out mice of Rab3A (Geppert
 
et al., 1994) and Rab3D 
(Riedel et al., 2002) have relatively mild neural phenotypes with the mice surviving till 
adulthood.  Rab3 mutation in C. elegans (Nonet et al., 1997) is also non-lethal. Further 
investigations revealed that while the regulation of synaptic vesicle exocytosis is 
abnormal in Rab3A-deleted mice, but exocytosis per se is
 
not impaired (Geppert et al.,
 
1997). In the Rab3D knockout mice, the size of the secretory granules in both exocrine 
pancreas and parotid glands was significantly increased. However, there was no change 
in overall exocytosis (Riedel et al., 2002). Analysis of rabphilin (a Rab3 effector) 
knockout mice also revealed no abnormalities in synaptic transmission or plasticity. 
Interestingly, the synaptic properties that were impaired in Rab3A knockout mice were 
unchanged in rabphilin knockout mice (Schluter et al., 1999). The authors have generated 
multiple knockouts for the Rab3 isoforms, and found that all single and double Rab3 
knock-out mice are viable and fertile. However, knocking out Rab3A with two other 
Rab3s will result in embryonic lethality, while triple knockout mice of Rab3B, Rab3C 
and Rab3D (BCD
-/-
) were fully viable, even when the remaining Rab3A gene was a 
heterozygous mutant. Quadruple knock-out mice appeared to develop normally during 
gestation but die shortly after birth due to respiratory failure. There was no apparent 
change in synaptic structure or spontaneous neurotransmitter release. However, there was 
a loss of rabphilin. Excitatory postsynaptic current (EPSC) in cultured hippocampal 
neurons from these mice was also about 30% smaller than control mice, caused 
apparently by a marked decline in synaptic vesicle release probabilities. Thus, Rab3 
proteins appear to be essential for the normal regulation of Ca
2+
-triggered synaptic 
vesicle exocytosis, rather than for synaptic vesicle exocytosis per se. This notion is in line 
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with the finding that both Rab3A and Rim1 are required for mossy fibre long-term 
potentiation (LTP) in the hippocampus (Lonart et al., 1998; Castillo et al., 1997, 2002). 
Although a detail molecular sequence of action involving Rab3 in synaptic vesicle 
exocytosis at the presynaptic compartment is not yet available, the GTP-dependent 
binding of Rab3 to RIM1/2 appears to allow it to regulate a Rim-based 
macromolecular complex (Munc13, RIM-binding proteins and -liprins), that in turn 
engages the SNAREs (syntaxin and SNAP-25) directly mediating synaptic vesicle fusion 
(Sudhof, 2004).  
 
 
Besides Rab3, only members of the Rab11 family (Rab11A, 11B, and 25) can 
influence Ca
2+
-induced exocytosis of neurotransmitters when over-expressed (Khvotchev 
et al., 2003), with the brain-enriched Rab11B having the strongest effect. Rab11B co-
fractionates with other secretory vesicle proteins such as synaptophysin, synaptotagmin 
and Rab3A in PC12 cells. It can also be found enriched in mature synaptic vesicles of the 
rat brain. Both the GDP-restricted and GTP-restricted Rab11B inhibited Ca
2+
-induced 
exocytosis, but the inhibitions likely occur via different mechanisms. The GDP-restricted 
Rab11B stimulated constitutive secretion of human growth hormone (hGH) transfected 
into PC12 cells, and depleted hGH stores in secretory vesicles. On the other hand, GTP-
restricted Rab11B affects constitutive secretion only moderately, and had no effect on 
vesicular hGH stores. Therefore, while GTP-restricted Rab11B could directly impaired 
Ca
2+
-triggered exocytosis, the GDP-restricted Rab11B may act in a more indirect manner. 
Thus, Rab11, besides playing important roles in retinal development of the eye and 
embryogenesis, also appears to have a specific role in neuronal and neuroendocrine cells 
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as a GTP-dependent switch that could shunt certain cargoes between the regulated and 
constitutive secretory pathways. 
  
Rab5 is localized both to synaptic vesicles and endosomal intermediates and was 
also discovered to be involved in synaptic vesicle recycling (Fischer von Mollard et al., 
1994). Investigators had expected Rab5 to be involved in recycling of membranes 
required for formation of synaptic vesicles but studies in Drosophila had shown that a 
dominant-negative Rab5, Rab5-N142I, induces an enlargement of synaptic vesicles in fly 
photoreceptor cells (Shimizu et al., 2003). This enlargement could be suppressed by 
enhancing synaptic vesicle recycling. The larger synaptic vesicles prepared from Rab5 
N142I-expressing flies also exhibited enhanced homotypic fusion in vitro. Therefore, 
instead of regulating the recycling of materials required for forming synaptic vesicles, 
Rab5 may function to keep the size of synaptic vesicles uniform by preventing their 
homotypic fusion through mechanisms that are not clear at this moment.  
  
Besides regulating rhodopsin trafficking during retinal development, Rab8’s 
somatodendritic localization suggests that it may also be involved in mediating dendritic-
specific transport processes. Investigations had shown Rab8 appears to have a critical 
role in the delivery of -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-
type glutamatergic receptors into the postsynaptic compartment. Although mainly TGN-
localized, Rab8 is found also in close proximity to the postsynaptic plasma membrane 
and the postsynaptic density (Gerges et al., 2004). Rab8 seemed to regulate a specific 
step in the local delivery of AMPA receptors into the synapses. While it is required for 
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AMPA receptor delivery into the synapse at the surface of dendritic spines, it is not 
required for the transport of AMPA receptor along the dendritic shaft into the spine 
compartment or their delivery to the general dendritic membrane surface. 
  
The insertion and removal of AMPA receptors from the postsynaptic plasma 
membrane is the primary activity underlying the phenomenon of both long-term 
potentiation (LTP) and long-term depression (LTD), which are experimental 
manifestations of synaptic plasticity (Malinow and Malenka, 2002). In the case of LTP, 
AMPA receptors are rapidly transported
 
from recycling endosomes to the plasma 
membrane (Park et al., 2004). In LTD, AMPA receptors are rapidly removed from the 
postsynaptic membranes in a step mediated by Rab5 (as discussed below) (Brown et al., 
2005).  
 
Like Rab8, Rab11 also has a role in AMPA receptor trafficking and LTP, and 
LTP can be blocked by overexpressing Rab11A dominant negative mutant. A generally 
agreed notion is that Rab11 mediate the translocation of AMPA receptors along the 
dendritic spine while Rab8 mediate the final delivery of AMPA receptors into the spine 
membrane (Brown et al., 2007). Since removal of AMPA receptors from the postsynaptic 
plasma membrane in LTD would involve endocytosis, the endosomal Rab5 protein is 
therefore predictably a prime regulator of at least part of this process. Rab5 is 
ultrastructurally localized to CA1 hippocampal synapses, and has indeed been shown to 
link the signaling cascades triggered by LTD induction and the endocytic machinery that 
executes the activity-dependent surface removal of AMPA receptors (Brown et al., 2005). 
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Rab5 activation drives the specific internalization of synaptic AMPA receptors in a 
clathrin-dependent manner. This rapid internalization of AMPA receptors by Rab5 is 
required for LTD as the overexpression of dominant-negative Rab5 inhibits LTD 
induction. N-methyl D-acetate (NMDA) receptor-dependent LTD induction 
(experimentally induced by a brief application of NMDA to hippocampal slices) 
produces a rapid and transient burst of Rab5 activation.  Rab5 does not, however, 
participates in the constitutive cycling of AMPA receptors. Although the details remained 
elusive, the emerging rough picture is that synaptic activity activates Rab5, which in turn 
drives the removal of AMPA receptors from synapses into the endosomes. 
 
1.2.4 Rab proteins in glia cells 
 
The glial cells made up 90% of the total number of cells in the brain. Recent 
findings indicate that glial cells do not simply hold the architecture of the human brain 
together, but play essential roles in brain development (Mori et al., 2005; Pereanu et al., 
2006) and the modulation synaptic transmission (Araque et al., 2004). There are three 
main types of glia cells in the central nervous system. The astrocytes are the most 
abundant glia. Astrocytic processes, known as end-feet, are in close-contact with 
neuronal processes serving in neurotransmitters re-uptake (Hertz and Zielke, 2004), and 
these may also wrapped around blood vessels to form the blood-brain barrier (Abbott, 
2002). Oligodendrocytes, on the other hand, wrap their processes around axons to form 
myelin sheaths (Simons and Trajkovic, 2006). The microglia is the equivalence of 
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immune cells in the CNS, playing roles in CNS inflammatory responses and serving in 
phagocytotic clearing of dead cells and debris (Mallat et al., 2005).  
 
Knowledge about the role of Rabs in glia specific functions are scarce compared 
to that of neurons. Ayala et al., 1989, were the first to report the expression of Rab3 in 
astrocytes. The authors reported two transcripts, 1.8kb and 1.3kb, in the brain, with the 
shorter 1.3kb transcript present in both neurons and astrocytes. Madison et al., (1996), 
reported that the various isoforms of Rab3 were differentially expressed in 
oligodendrocytes (Rab3A and Rab3C) and astrocytes (Rab3B) (Madison et al., 1996). 
This was not surprising as the Rab3A’s GDI was detected in the homogenates of cultured 
rat hippocampus and astrocytes in an earlier study (Motoike et al., 1993). This also 
indicates that the GDI may regulate membrane trafficking in both neurons and glial cells 
by interacting with members of the Rab GTPases family. 
 
Relatively little is known about microglia-specific Rabs. However, unlike Rab6A 
and A’ which are ubiquitously expressed, a paralogue of these Golgi Rabs, Rab6B, was 
found to be enriched in the brain and expressed in the microglia, pericytes and Purkinje 
neurons (Opdam et al., 2000). In a recent study, Rab6B was shown to be involved in 
retrograde trafficking in SK-N-SH neuroblastoma cells via interaction with Bicaudal-D1, 
a large coiled-coil protein known to bind to the dynein/dynactin complex (Wanschers et 
al., 2007). As mammalian Bicaudal-Ds also interact with Rab6A, this is unlikely to be a 




 Recently, another Rab GTPase, Rab40C, was cloned from an oligodendrocyte 
cDNA library (Rodriguez-Gabin et al., 2004). Its’ transcript was found to be enriched in 
oligodendrocytes, oligodendrocyte progenitors, microglial and astrocytes. However, 
Rab40C transcript levels appear to be upregulated in mature oligodendrocytes. 
Localization experiments done with EGFP-tagged Rab40C in HeLa cells revealed it to be 
localized to the perinuclear recycling endosomes, a compartment which acts as a transit 
for receptors and other cellular components which may be targeted back to the cell 
surface or the lysosomes for degradation (Mellman, 1996). As an oligodendrocyte could 
simultaneously wrap myelin around several axons, the perinuclear recycling endosomes 
may thus play a crucial role by allowing cellular components to be targeted to multiple 
domains. Rab40C’s role in the CNS is unclear, but its’ enrichment in oligodendrocytes 
and localization in the perinuclear recycling compartments suggest that it may function in 
myelination.  
 
 Lastly, the Rab protein which is my main research focus, Rab22B, was first 
cloned in 1996 (Chen et al., 1996). Its transcripts are found in abundance in 
oligodendrocytes, and to a lesser extent, in astrocytes and microglia (Burcelin et al., 
1997). In another report, the authors observed that tubulo-vesicular transport vesicles 
containing Rab22B exiting the TGN and transiting to the plasma membrane via the early 
endosomes (Rodriguez-Gabin et al., 2001). Thus, the authors suggest that the regulation 
of trafficking of membrane components by Rab22B may play an important role in myelin 
formation and maintenance in oligodendrocytes.   
 
Aims and rationale of current work 
27 
1.3 Aims and rationale of current work 
 
One of the main research focuses of the lab is to understand the role of various 
trafficking components in the CNS. Previous work by other groups (Burcelin et al., 1997; 
Rodriguez-Gabin et al., 2001) had shown that Rab22B is a brain-enriched Rab. However, 
nothing is known about the cell-type localization in the brain and cellular function. 
Therefore, the project has two main aims.  
 
Firstly, I sought to characterize this intriguing Rab GTPase in terms of cellular 
and tissue localization. Secondly, I attempted to investigate Rab22B’s cellular function. 
With regards to the first aim, during the course of the investigation, specific reagents 
were developed to allow the demonstration of Rab22B’s enrichment in the astroglia 
lineage. Pertaining to the second aim, my work revealed that Rab22B plays a role in 
anterograde TGN traffic. Rab22B also appears to modulate EGFR’s endocytic itinerary 
and signaling. These and other findings are detailed in Section 3. As previous studies had 
indicated that Rab22B’s transcripts are enriched in glia cells, these ground works are 
necessary to help delineate the role that Rab22B may play in CNS development and 
neuron-glia biology. 
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2. Materials & methods 
 
2.1  Cell culture  
 
 Various molecular and trafficking assays were conducted using cell lines such as 
HeLa (a human cervical carcinoma cell line), A431 (a human skin carcinoma cell line), 
HEK293 (a human epithelial kidney cell line), U87 (a human glioblastoma cell line), 
158N (mouse oligodendroglia cell line) and OLN93 (rat oligodendroglia cell line). The 
former four cell lines were obtained from the American Type Culture Collection (ATCC, 
United States of America) while 158N and OLN93 were generous gifts from Prof. M. S. 
Ghandour (Institute of Physical Biology, Strasbourg, France) and Prof. Zhicheng Xiao 
(Neurobiology Laboratory, Department of Clinical Research, Singapore General 
Hospital). All the cell lines were maintained in a humidified incubator at 37
o
C with 5% 
carbon dioxide (CO2). 
 
2.1.1 Preparation and maintenance of primary astrocytes, oligodendrocytes and 
neurons 
 
Primary cell lines of astrocytes and oligodendrocytes were obtained from post-
natal stage (P) 1-2 days’ Sprague Dawley pups to probe for the presence of Rab22B. 
Primary cell line of neurons was also obtained from embryonic stage (E) 14-16 pregnant 
CL57/B16 mice to confirm the absence of Rab22B. The presence or absence of Rab22B 
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Fig. 2.1: Schematic diagram illustrating the procedures for isolation of astrocytes and 
oligodendrocytes from rat pups.  
 
Preparation and maintenance of primary astrocytes and oligodendrocytes 
 
Mixed glial cells were isolated from six brains of P1-2 Sprague Dawley pups. 
Briefly, the brains were removed from the skull and rinsed with DMEM/F12 (Invitrogen: 
11330-032) to remove blood. The meninges were removed and the brains were minced 
into 1mm
3
 pieces before subjecting to enzymatic digestion with 6mL of 0.1% of 
trypsin/EDTA (Invitrogen: 25200-056)  at 37
o
C for 30 minutes. Upon completion of 
enzymatic digestion, trypsin was inactivated with 18mL of DMEM/F12, supplemented 
P1
220rpm/16-18hours 
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with 10% fetal bovine serum (FBS) (Biowest: S1830). The mixed glial cell suspension 
was triturated with a glass Pasteur pipet and filtered through a 70m Nylon filter (BD 
Falcon: 352350). The filtered mixed glial cell suspension was then plated onto three 
75cm
2
 flasks pre-coated with 2mL of 30g/mL of poly-L-lysine (Sigma: P5899). 
Alternatively, when the mixed glia culture (or other cell types) was required for 
immunocytochemistry, the cells were plated onto 12mm glass coverslips (Fisher 
Scientific: 12-545-80) placed in the wells of a 24-well plate. The coverslips were also 
pre-coated with 30g/mL of poly-L-lysine.  The mixed glial culture was maintained in 
DMEM/F12 supplemented with 10% FBS, 1mM sodium pyruvate (Invitrogen: 11360-
070) and 1% antibiotics-antimycotics (100U/mL of penicillin sodium salt, 100g/mL of 
streptomycin sulfate and 25g/mL of amphotericin B) (Invitrogen: 15240-062). The 
media was routinely changed every 2-3 days.  
 
To isolate oligodendrocytes, the flasks were subjected to vigorous shaking on a 
rotary shaker (220rpm, 16-18 hours) after the monolayer of mixed glia cells was 
confluent. Oligodendrocytes, which are less adherent compared to astrocytes, would be 
dislodged into the culture media. The media was collected and filtered through a 70m 
Nylon filter. The filtered media was then centrifudged at 1000g for 5 minutes. The cell 
pellet was then plated onto a 60mm plate, which was pre-coated with 0.5mL of 30g/mL 
of poly-L-lysine. For experiments whereby oligodendrocytes were required for 
immunocytochemistry, coverslips, which were pre-coated with 30g/mL of poly-L-lysine, 
were placed in the same 60mm plate. The oligodendrocyte culture was maintained in 
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DMEM/F12 supplemented with 10% FBS, 1mM sodium pyruvate and 1% antibiotics-
antimycotics and the media was routinely changed every 2-3 days. 
The astrocytes’ monolayer which remained after the dislodgement of 
oligodendrocytes would be  trypsinized and re-plated onto coverslips, which were pre-
coated with 30g/mL of poly-L-lysine for immunocytochemistry analysis. 
 
Preparation and maintenance of primary neurons 
 
Primary neurons were isolated from the brains of E14-16 CL57/B16 mice. 
Typically, embryos were removed from the mother’s abdomen and blood was rinsed off 
the embryos with Hank’s medium, supplemented with 1% antibiotics-antimycotics and 
buffered with 10mM, pH7.4 Hepes (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
(Sigma: H4034). The brains were then removed from the skull and meninges were 
removed. Thereafter, the brains were minced into sizes of about 1mm
3
 and digested in 
0.25% of typsin/EDTA and 25g/mL of DNaseI (Sigma: D5025), at 37oC for 10 minutes. 
Typically, four-six brains would be harvested and digested in a total volume of 2mL of 
0.25% of trypsin/EDTA and 25g/mL of DNaseI. After enzymatic digestion, the mixture 
of trypsin/EDTA and DNaseI would be removed and replaced with 2mL of plating 
medium which is made up of MEM (Invitrogen: 11095-080), supplemented with 0.05% 
sodium bicarbonate (Sigma: S6297), 1mM sodium pyruvate, 10% FBS and 1% 
antibiotics-antimycotics. The digested tissues were then triturated with a glass Pasteur 
pipette. Upon triturating, the cells were plated into poly-L-lysine pre-coated 100mm 
tissue culture plates (typically, cells were seeded at about two brains per 100mm tissue 
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culture plate). Coverslips, which were pre-coated with 30g/mL of poly-L-lysine, were 
placed in the same plate. For the first 24 hours, the neurons were maintained in plating 
medium. Thereafter, for the next 7-9 days, the neurons were maintained in Neurobasal 
medium (Invitrogen: 21103-049), supplemented with 1x B27 (Invitrogen: 10889-038) 
and 10mM L-glutamine (Invitrogen: 25030-081). The media was refreshed every 2-3 
days. 
 
2.1.2  Maintenance of mammalian cell lines 
 
 Maintenance of HeLa and A431 
 
 HeLa and A431 cells were obtained from ATCC and maintained as follows. 
Briefly, the cells were maintained in DMEM (Sigma: D1152) supplemented with 10% 
FBS, 1mM sodium pyruvate, 2mM L-glutamine and 1% antibiotics-antimycotics. The 
culture media were changed every 2-3 days and the cells were subcultured once every 
week, at a 1:10 ratio. 
 
 Maintenance of HEK29, U87, OLN93 and 158N 
  
 HEK293 and U87 cell lines were obtained from ATCC. The maintenance of 
OLN93 and 158N were similar to that of HEK293 and U87. Briefly, cells were 
maintained in RPMI (Sigma: R1383) supplemented with 10% FBS, 1mM sodium 
pyruvate (Invitrogen: 11360-070) and 1% antibiotics-antimycotics (Invitrogen: 15240-
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062). The culture media were changed every 2-3 days. The cells were subcultured twice 
every week, at a 1:20 ratio.  
 
2.2 Transfection of mammalian cell lines 
 
Transfection of cells was carried out in experiments to assess if there was any 
biochemical/molecular change when Rab22B or its’ mutant, Rab22B S20N - a GDP-
restricted form of Rab22B, was over-expressed or when endogenous Rab22B was 
depleted in the cell lines described above. The efficiency and effect of transfection was 
typically assessed via immunocytochemistry, Western immunoblot or trafficking assays. 
 
2.2.1 Transfecting mammalian cell lines with expression constructs 
 
 Transfection using Effectene 
 
 Plasmid constructs were transfected into HeLa cells using a cation-lipid mediated 
transfection kit, Effectene Transfection Reagent (Qiagen: 301427). Typically, for a single 
well of a 24-well plate, a total of 1g of DNA was diluted in 240L of the 
manufacturer’s supplied buffer, before the addition of 6.4L of enhancing reagent, which 
helps to coil up the DNA to enhance better encapsulation by Effectene. The mixture was 
incubated for 5 minutes at room temperature. Finally, 20L of Effectene was added to the 
mixture and further incubated for another 20 minutes at room temperature.  The spent 
medium was removed and replaced with 1mL of complete medium, i.e., DMEM 
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supplemented with 10% FBS, 1mM sodium pyruvate, 2mM L-glutamine and 1% 
antibiotics-antimycotics. The Effectene-DNA complexes were added to the cells and 
removal of complexes was done after 7-8 hours of incubation. Cells were rinsed with 
basal DMEM before addition of maintaining medium. Thereafter, cells were returned to 
the incubator and further incubated for another 16-18 hours. 
 
Transfection using Lipofectamine 2000 
 
 Plasmid constructs were transfected into A431 cells using another cation-lipid 
mediated transfection kit, Lipofectamine 2000 Transfection Reagent (Invitrogen: 11668-
500). Typically, for a single well of a 24-well plate, a total of 1g of DNA was diluted in 
50L of Opti-MEM (Invitrogen: 31985-062) and 3L of Lipofectamine 2000 was diluted 
in 50L of Opti-MEM in two separate tubes and incubated at room temperature for 5 
minutes. Upon this incubation, the diluted Lipofectamine was added to the diluted DNA 
and further incubated for another 20 minutes at room temperature. The spent medium was 
removed and replaced with 1mL of fresh complete medium. The Lipofectamine-DNA 
complexes were added to the cells and removal of complexes was done after 7-8 hours of 
incubation. Cells were rinsed with basal DMEM before addition of maintaining medium. 
Thereafter, cells were returned to the incubator and further incubated for another 16-18 
hours. 
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2.2.2 Transfecting mammalian cell lines with si(small-interfering)RNA 
 
 Transfecting siRNA into mammalian cell lines using Lipofectamine RNAiMAX 
 
 27mer siRNA (Integrated DNA Technologies Inc., Coralville, IA) was introduced 
into HeLa or A431 using Lipofectamine RNAiMAX (Invitrogen: 13778-150). siRNA 
targeting Rab22B was based on the sequence: 5’---
GTGCCTTGTGGAAATGAACTTCACA---3’. siRNA targeting GAPex-5 (or GTPase-
activating protein and VPS9 domain-containing protein 1 (GAPVD1)) was based on the 
sequence: 5’---AAGAATCGATTACCTATAGCAACTC---3’. Typically, the effects of 
depleting Rab22B or GAPex-5 were assessed via immunocytochemistry or Western 
immunoblot. Coverslips, pre-coated with poly-L-lysine, were placed in 60mm plate 
before plating of cells. Cells grown on the coverslips were fixed with 4% 
paraformaldehyde for immunocytochemistry analysis and the remaining cells on the 
60mm plate were subjected to lysis for Western immunoblot.  
 
 Routinely, for each 60mm plate, 50pmol of siRNA was diluted in 250L of Opti-
MEM and 5L of Lipofectamine RNAiMAX was diluted in 250L of Opti-MEM in two 
separate tubes and incubated at room temperature for 5 minutes. Upon this incubation, 
the diluted Lipofectamine RNAiMAX was added to the diluted siRNA and further 
incubated for another 20 minutes at room temperature. The spent medium was removed 
and replaced with 2.5mL of complete medium. The Lipofectamine RNAiMAX-siRNA 
complexes were added to the cells and removal of complexes was done after 7-8 hours of 
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incubation. Cells were rinsed with basal medium before addition of complete medium. 
Thereafter, cells were returned to the incubator and further incubated for another 48 hours. 
 
2.2.3 Generation of Rab22A/Rab22B-expressing stable clones 
 
 HEK293 clones stably expressing Rab22A and Rab22B were generated to check 
for the specificity of Rab22B antibody and siRNA targeting Rab22B. 
 
 Rab22A and Rab22B constructs were transfected into HEK293 cells as described 
in Section 2.2.1. Typically, for a 60mm plate, a total of 2g of DNA was used.  
 
 After 16-18 hours, the cells were subcultured at a 1:5 ratio into 100mm plates. To 
select positive clones, geneticin (G418) (Invitrogen: 11811-031) was added to a final 
concentration of 1.2mg/mL after another 24 hours of incubation. Non-Rab22A or 
Rab22B cells would be removed upon the addition of G418. Positive clones would 
normally appear after 7-8 days after the addition of G418.  
 
2.3 Trafficking assays 
  
2.3.1 Shiga toxin uptake and transport 
 
 Shiga toxin was generously provided by Prof. Wanjin Hong (Institute of 
Molecular and Cell Biology, Singapore). Shiga toxin was diluted to 0.01mg/mL with 
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basal DMEM before usage. Shiga toxin was bound to HeLa, which was over-expressing 
or depleted of Rab22B, by incubating the cells with the toxin on ice for 30 minutes. 
Thereafter, cells were incubated at 18
o
C for 60 minutes (to allow internalization of toxin) 
before removal of the toxin. Cells were rinsed with chilled basal DMEM and the pulse at 
18
o
C was continued for another 30 minutes. Basal medium was removed before the 
addition of pre-warmed complete medium. Upon the addition of pre-warmed complete 
medium, the cells were returned to normal incubating conditions (to allow endosome-
TGN transport) and fixed at 60 minutes. 
  
2.3.2 Transferrin (Tf) uptake and transport 
 
 Fluorescein-isothiocynate (FITC)-tagged Tf was purchased from Molecular 
Probes (T7281) and diluted to a working concentration of 0.005mg/mL with basal 
DMEM. FITC-Tf was first bound to HeLa or A431 cells over-expressing or depleted of 
Rab22B, by incubating the cells with FITC-Tf on ice for 30 minutes. Thereafter, cells 
were incubated at 18
o
C for 60 minutes (to allow internalization of FITC-Tf). Cells were 
then rinsed with chilled basal DMEM and the pulse at 18
o
C was continued for another 30 
minutes. Basal medium was removed before the addition of pre-warmed complete 
medium. Upon the addition of pre-warmed complete medium, the cells were returned to 
normal incubating conditions and fixed at the time-point of 10 minutes and 20 minutes. 
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2.3.3 Epidermal growth factor (EGF) uptake and transport 
 
 Uptake and transport of Texas-red-tagged or non-conjugated EGF 
  
 Texas-red (also known as sulforhodamine 101 acid chloride) (TxR)-tagged EGF 
was purchased from Molecular Probes (E3480) and diluted to a working concentration of 
0.002mg/mL with basal DMEM. Non-conjugated EGF was purchased from PeproTech 
(100-15) and diluted to a working concentration of 0.001mg/mL with basal DMEM. 
A431 cells, which was overexpressing or depleted of Rab22B, was pulsed with the 
diluted TxR-EGF for 5 minutes. Thereafter, cells were rinsed with chilled basal DMEM 
and the chase was performed in pre-warmed complete medium for 5 and 60 minutes, 
respectively before fixing with 4% paraformaldehyde for immunocytochemistry analysis.  
 
2.3.4 Monitoring vesicular stomatitis viral glycoprotein (VSVG) transport  
 
 The VSVG (temperature sensitive (ts)045)-YFP) (VSVGts045) expression 
construct was generously provided by Prof. Alexander Mironov (Department of Cell 
Biology and Oncology, Consorzio Mario Negri Sud, Italy). To check if the 
overexpression wild-type Rab22B, Rab22B WT or the GTP-deficient Rab22B, Rab22B 
S20N had any effect on the exit of the viral glycoprotein, the VSVGts045 construct was 
co-transfected with expression constructs of wild-type Rab22B, Rab22B WT or the GTP-
deficient Rab22B, Rab22B S20N (0.75g of VSVGts045 and 0.25g of Rab22B 
constructs) into HeLa cells. Similarly, to check if the depletion of endogenous Rab22B 
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had any effect on the exit of this viral glycoprotein, HeLa cells was first transfected with 
siRNA targeting Rab22B for 48 hours before transfecting VSVGts045. 16-18 hours upon 
transfecting VSVGts045, HeLa cells were then incubated at 39.5
o
C for 40 minutes (to 
trap newly-synthesized vial glycoprotein at the endoplasmic reticulum and synchronize 
their exit), followed by a shift to 32
o
C for 5 hours (to allow the exit of the viral 
glycoprotein from the endoplasmic reticulum). Cells were then fixed for 
immunocytochemistry analysis. 
 
2.4 Immunofluorescence assays and confocal microscopy imaging 
 
 In principle, the immunohistochemistry and immunocytochemistry assays are 
largely similar, with minor differences in the technical details. Section 2.4.1 and 2.4.2 




 Sample preparation 
 
Ultrathin, cyrosections of 20m were obtained from either fetal or adult mouse’s 
(C57/BL6) brain using a cryo-microtome. Briefly, for fetal mouse’s brain, the mother 
was anaesthetized before perfusion. The mouse was first perfused with saline followed by 
paraformaldehyde before the fetuses were drawn out from the mother’s abdomen. 
Thereafter, the placental sac was removed and the entire fetus was post-fixed in 
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paraformaldehyde, overnight at 4
o
C. Upon post-fixation, the fetus was placed into 
cryomatrix and frozen with liquid nitrogen before cryo-sectioning.  
 
 Similarly, for adult mouse’s brain, the adult mouse was also anaesthetized before 
perfusion. The mouse was first perfused with saline followed by paraformaldehyde. 
Thereafter, the brain would be removed from the skull and post-fixed in 
paraformaldehyde, overnight at 4
o
C. The next day, the tissue was placed into cryomatrix 
and frozen with liquid nitrogen before cryo-sectioning.  
 
 Labeling sections with fluorophores 
 
 Upon cryo-sectioning, the brain sections were stored in a -80
o
C freezer. Before 
labeling the section with fluorophores, the sections were thawed in phosphate buffered 
saline (PBS; 137mM sodium chloride, 2.7mM potassium chloride, 3mM di-sodium 
hydrogen phosphate and 1.47mM potassium di-hydrogen phosphate), pH7.4. After 
thawing, the section would be rinsed 3x with 100mM ammonium chloride in PBS. Each 
rinse was for 10 minutes and carried out at room temperature. This is to quench free 
aldehyde groups from the paraformaldehyde which may interfere with antibody-antigen 
binding. Upon rinsing with ammonium chloride/PBS, the section was rinsed with PBS 
before it was permeabilized with 0.1% Triton-X100 in PBS, at room temperature for an 
hour. Thereafter, the sections were immuno-blocked with 10% donkey serum (Sigma: 
D9663) before being sequentially probed with primary antibodies and FITC- or TxR-
conjugated secondary antibodies. The primary antibodies were incubated with the tissue 
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section at room temperature for 4 hours. Following primary antibodies’ incubation, the 
tissue section was rinsed 3x with PBS before incubation with fluorophore-conjugated 
secondary antibodies. The secondary antibodies were incubated with the tissue section at 
room temperature for an hour before the section was again rinsed 3 times with PBS. 
Thereafter, the tissue was soaked in Hoechst 33342 (diluted to 0.001mg/mL) (Invitrogen: 
H3570) for 5 minutes and rinsed again before mounting with VectaShield (Vector 
Laboratories: H1000. After the addition of VectaShield, a glass coverslip was placed on 
top and sealed with nail polish.  
 
 Typically, the primary antibodies used for immunocytochemistry were: anti-
Rab22B (home-made rabbit polyclonal antibodies and mouse polyclonal antibodies), 
anti-GAPex5 (a rabbit polyclonal antibody, generously provided by Prof. Alan Saltiel, 
University of Michigan). The rest of the antibodies were monoclonal antibodies, unless 
stated otherwise. They were RC2 – a antibody marker for radial glia (which recognizes 
an epitope located on the glial cytoskeleton and identified as an intermediate filament 
associated protein (IFAP) (Developmental Studies Hybridoma Bank, University of Iowa), 
anti-GFAP – a marker for mature astrocyte (Sigma: G3893), anti-CNPase (2',3'-cyclic 
nucleotide 3'-phosphodiesterase) – a marker for mature oligodendrocyte (Chemicon: 
MAB326), anti-TuJ (III-tubulin) – a marker for mature neuron (Sigma: T8660), anti-
A2B5 – a marker for neuronal and oligodendrocyte progenitor cell (Chemicon: MAB312) 
and anti-nestin – a marker for neuronal progenitor cell (Abcam: AB6142).  
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 The secondary antibodies were purchased from Jackson Immunoresearch 
Laboratories (JIR) and were typically used in the combinations of donkey anti-rabbit 
FITC immunoglobulins (Ig) (JIR: 711-095-152) and donkey anti-mouse TxR Ig (JIR: 
715-075-150) OR donkey anti-mouse FITC Ig (JIR: 715-095-150) and donkey anti-rabbit 




 Cells were grown on coverslips and fixed with 4% paraformaldehyde (Sigma: 
P6148). After fixing, the cells were rinsed 3 times with 100mM ammonium chloride in 
PBS. Each rinse was for 5 minutes and carried out at room temperature. Upon rinsing 
with ammonium chloride/PBS, the cells were permeabilized with 0.025% saponin (Sigma: 
S4521) in PBS, at room temperature for 10 minutes. Thereafter, the cells were 
sequentially being probed with primary antibodies and FITC- or TxR-conjugated 
secondary antibodies. The primary antibodies were incubated with the cells at room 
temperature for 40 minutes. Following primary antibodies’ incubation, the tissue section 
was rinsed 3x with PBS and soaked in 0.025% saponin/PBS for 1 minute before 
incubation with fluorophore-conjuagted secondary antibodies. The secondary antibodies 
were incubated with the tissue section at room temperature for 30 minutes before the 
section was again rinsed 3 times with PBS. Thereafter, a small drop of VectaShield 
(Vector Laboratories: H1000) was placed on a glass slide. The coverslip was inverted 
onto the drop of the VectaShield and sealed with nail polish.  
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 Typically, the primary antibodies used for immunocytochemistry were anti-
Rab22B (as described above). The rest of the antibodies were monoclonal antibodies, 
unless stated otherwise. They are sheep anti-TGN46 (trans-Golgi network) – a marker for 
the trans-Golgi network (Serotec: AHP500), anti-GM130 (Golgi-matrix protein) – marker 
for cis-Golgi (BD Biosciences: 610823), anti-M6PR (mannose 6’phosphate receptor) – a 
late endosome marker (a generous gift from Prof. Stuart Kornfield, Washington School of 
Medicine, USA), anti-GFAP (as described above) and anti-CNPase (as described above). 
 
 The secondary antibodies were purchased from Jackson Immunoresearch 
Laboratories and were typically used in the combinations of donkey anti-rabbit FITC Ig 
and donkey anti-mouse TxR Ig OR donkey anti-mouse FITC Ig and donkey anti-rabbit 
TxR Ig OR donkey anti-rabbit TxR Ig and donkey anti-sheep FITC Ig (JIR: 713-075-003). 
 
2.4.3 Confocal microscopy and imaging 
 
 Fluorescence labeling was visualized and imaged using an Axiophot microscope 
(Carl Zeiss), equipped with the Carl Zeiss 510 confocal imaging scan-head and software. 
Typically, most images were collected in separate Z sections and final presented images 
were often from collapsed Z-stacks (Fig. 2.2).  
Materials & methods 
44 
 
Fig. 2.2: A typical image taken with the confocal microscope. Image taken shows the 
presence of Rab22B in astrocytes, co-localizing with GFAP.  
 
2.5 Deoxyribonucleic acid (DNA) and protein manipulation 
 
2.5.1 Polymerase chain reaction 
 
 Polymerase chain reaction (PCR) was employed to amplify DNA from human 
Rab22B (IMAGE clone: 4792577; GI: 13981614) and human Rab22A expressed 
sequence tag (IMAGE clone: 3907891; GI: 16041683) clones, which were obtained from 
Invitrogen. The amplified DNA fragment was then cloned into a bacterial or mammalian 
expression vector (to be described in Section 2.5.2).  
 
Typically, the following conditions were used to amplify the DNA fragment:  
- Denaturing of template: 95
o
C – 5 minutes 
- Amplification cycles: 95
o
C – 1 minute 
                58
o
C – 1 minute 
                                      72
o
C - 1 minute 
- Elongation of amplified products: 72
o
C – 15 minutes 
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For expression construct carrying point mutation, e.g., pCI-Neo::Rab22B-SN, 
nested PCR was carried out using a pair of nested primers carrying the required mutation. 
 
The recombinant DNA was then transformed into a bacterial vector, DH5 
(Invitrogen: 18265017). Upon transformation, DNA was extracted from the bacterial 
vector using a miniprep kit (Promega: A1460) and the extracted DNA were then 
subjected to restriction enzyme digests and agarose gel electrophoresis to confirm if the 
right fragment had been cloned into the expression vector (Fig. 2.3).  
                                                     
Fig. 2.3: A typical picture of analysis performed with an agarose gel electrophoresis. 
Leftmost lane is the 2-log DNA molecular ladder (New England Biolabs: N3200S), 




(from left) lane are the 
expression vector and the lower bands are the cloned DNA insert. 
 
 
2.5.2 Bacterial and mammalian expression constructs 
 
 Vector used for generating expression constructs 
 
The bacterial expression vector used pGEX-4T-1 carries a glutathione-S-
transferase (GST) tag (Amersham Biosciences: 27-4580-01) (Fig. 2.4).  
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Fig.   2.4:    Vector   map    of   pGEX-4T-1.   The    pGEX-4T-1    bacterial   expression  
vector   carries    the     tac    promoter     region   to   allow   the   inducible   expression  
of   cloned   DNA in  bacterial  cells.  The    vector    also   contains  the ampicillin 
(Amp
R




The mammalian expression vectors used were pCI-Neo (Promega: TB215) (Fig. 
2.5) and pDMyc, which is a modification of the pCI-Neo vector. It carries a myc-tag at 
1085-1091bp of the multiple cloning sites (MCS) of pCI-Neo, thereby removing NheI as 
one of the MCS (refer to Fig. 2.5). 
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Fig. 2.5: Vector map of pCI-Neo. The pCI-Neo mammalian expression vector carries the 
human cytomegalovirus (CMV) immediate-early (I.E.) enhancer/promoter region to 
promote constitutive expression of cloned DNA inserts. The vector also carries the 
neomycin phosphotransferase gene, a selectable marker for mammalian cells, which 
allows the selection of transfected cells with G418. Map is obtained from: 
http://www.promega.com/tbs/tb215/tb215.html . 
  
 Bacterial expression constructs 
 
 The following constructs were generated to express recombinant proteins in 
Escherichia coli (E. coli):  
- pGEX::Rab22B-C’. DNA used to clone this construct was amplified from the 
human Rab22B EST clone using the forward primer: 5’---
GCCGAATTCAAGAGCTCTTTCAAGGAATCAGCCG---3’ and reverse primer: 
5’---GGTAGTCGACTCAACAGCACCGGCGGCTGGCTTGCATGG---3’. This 
construct was used to express protein in a bacterial system which was then used as 
an antigen to immunize New Zealand white rabbits to produce Rab22B-specific 
antibodies.  
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- pGEX::Rab22B-WT (wild-type). DNA used to clone this construct was amplified 
from the human Rab22B EST clone using the forward primer: 5’---
CCGTGAATTCATGGCGATACGGGAGCTCAAAGTGTGCC---3’ and reverse 
primer:  5’---GGTAGTCGACTCAACAGCACCGGCGGCTGGCTTGCATGG--
-3’. Similarly, this protein was used to express protein in a bacterial system. 
However, the protein expressed with this construct was used affinity pull-down 
assays (to be described in Section 2.5.4). 
 
Mammalian expression constructs 
 
Mutant and chimeric forms of Rab22B constructs were generated to determine if 
their overexpression would exhibit features, subcellular localization or trafficking 
pathways that may be different from the wild type protein.  
 
The following constructs were generated to express recombinant proteins in the 
mammalian system:  
- pCI-Neo::Rab22B-WT: DNA used to clone this construct was amplified from the 
human Rab22B EST clone using the forward primer: 5’---
CTCGAATTCAATGATGGCGATACGGGAGCTC---3’ and reverse primer: 5’--
-TCGGTCGACTCAACAGCACCGGCGGCT---3’.  
- pCI-Neo::Rab22B-SN: DNA  used  to  clone  this   construct  was  amplified  
from the human  Rab22B  EST clone  using the forward primer: 5’---
CTCGAATTCAATGATGGCGATACGGGAGCTC---3’     and    reverse  primer:  
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5’---TCGGTCGACTCAACAGCACCGGCGGCT---3’.    In         addition,  a 
pair  of      nested    primers   carrying  the   required   mutation    was   also  used. 
The forward nested primer is: 5’---
ACTGGGGTTGGGAAAAATAGCATCGTGTGTCGA---3’ while the reverse 
nested primer is: 5’---TCGACACACGATGCTATTTTTCCCAACCCCAGT---3’. 
- pDMyc::Rab22B-WT: DNA used to clone this construct was amplified from the 
human Rab22B EST clone using the forward primer: 5’---
CCGTGAATTCAATGGCGATACGGGAGCTCAAAGTGTGCC---3’ and 
reverse primer: 5’---TCGGTCGACTCAACAGCACCGGCGGCT---3’. 
- pDMyc::Rab22B-SN: DNA used to clone this construct was amplified from the 
human Rab22B EST clone using the forward primer: 5’---
CCGTGAATTCAATGGCGATACGGGAGCTCAAAGTGTGCC---3’ and 
reverse primer: 5’---TCGGTCGACTCAACAGCACCGGCGGCT---3’. In 
addition, a pair of nested primers carrying the required mutation was also used. 
The forward nested primer is: 5’---
ACTGGGGTTGGGAAAAATAGCATCGTGTGTCGA---3’ while the reverse 
nested primer is: 5’---TCGACACACGATGCTATTTTTCCCAACCCCAGT---3’. 
- pDMyc::Rab22A-WT: DNA used to clone this construct was amplified from the 
human Rab22A EST clone using the forward primer: 5’---
GTGCTCGAGGCGCTGAGGGAGCTCAAAGTG---3’ and reverse primer: 5’---
GGT TCTAGATCAGCAGCAGCTCCGCTTTGG---3’. 
- pDMyc::Rab22A-SN: DNA used to clone this construct was amplified from the 
human Rab22A EST clone using the forward primer: 5’---
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GTGCTCGAGGCGCTGAGGGAGCTCAAAGTG---3’ and reverse primer: 5’---
GGT TCTAGATCAGCAGCAGCTCCGCTTTGG---3’. In addition, a pair of 
nested primers carrying the required mutation was also used. The forward nested 
primer is: 5’---GTGTAGGTAAAAATAGTATTGTGTG---3’ and the reverse 
nested primer is: 5’---CACACAATTCTATTTTTACCTACAC---3’. 
- pDMyc::Rab22ANter22BCter: For this chimeric construct, pDMyc::Rab22A was 
used as the vector. DNA used to clone this fusion construct was amplified from 
Rab22B EST clone. The forward primer used to clone the Rab22B fragment is: 
5’---GAATTCTTGGACCCCCATG---3’ and the reverse primer is 5’---
CGGGTCGACTCAACAGCACCGGCGGCTGGC---3’.  
- pDMyc::Rab22ACter22BNter: For this chimeric construct, pDMyc::Rab22A was 
also used as the vector. DNA used to clone this fusion construct was amplified 
from Rab22B EST clone. The forward primer used to clone the Rab22B fragment 
is: 5’---GTGCTCGAGGCGCTGAGGGAGCTCAAAGTG---3’ and the reverse 
primer is: 5’---CTCGAATTCAGCGGCTGATTCCTTGAAAGAGCTC---3’. 
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2.5.3  Large-scale induction of bacterial fusion proteins  
 
 Large quantities of bacterial culture were prepared from a single bacterial colony 
of pGEX-4T-1, pGEX::Rab22B-C’ or pGEX::Rab22BWT. Briefly, DNA from either 
construct was transformed into DH5. A single colony from the transformation was then 
inoculated into 3mL of Luria Bertani (LB) + ampicillin (100g/mL) and incubated at 
37
o
C for about 7-8 hours. This seed culture would serve as the primary inoculum for 
inoculation of 250mL of LB + ampicillin, which would be further incubated for another 
16-18 hours. After 16-18 hours’ of incubation, the bacterial culture would be diluted with 
more LB + ampicillin to about 0.1 at OD600. Thereafter, the bacterial culture would be 
allowed to grow to about 0.4-0.6 at OD600 before inducing with 0.1mM isopropyl -D-
1-thiogalactopyranoside (IPTG) (United States Biochemical: 17886) for about 4 hours. 
After IPTG induction, the culture would be centrifuged and a pellet was collected and 
resuspended in PBS, supplemented with 0.1mM of phenylmethanesulphonylfluoride 
(PMSF) (Sigma: 7626). This bacterial suspension was then sonicated to lyze the cells. 
Upon sonication, the suspension was centrifuged and the supernatant was collected. 
Glutathione-sepharose beads (Amersham Biosciences: 17-0756-04) was added to the 
supernatant to bind the GST-tagged recombinant protein. To elute the GST-tagged 
protein from the beads, the beads were washed 3x with PBS and eluted with PBS, pH7.4 
and 20mM reduced glutathione (GSH) (Sigma: G4251). Typically, about 10x 1mL 
fractions would be collected. The eluted protein mixture was dialyzed against PBS, with 
three changes of PBS after every ~7-8 hours. The dialyzed protein was subjected to 
Materials & methods 
52 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to estimate the 











Fig. 2.6: Picture showing SDS-PAGE analysis of fusion protein production. Rightmost 
lane is the Precision Plus All Blue Protein standards (BioRad: 161-0373). The bovine 




  lane (from left) are used as standards to estimate 





lane, respectively).  
 
2.5.4 Lysis of cultured cells or tissue  
 
Cells were also grown to confluency and lyzed with lysis buffer (50mM Tris-HCl, 
pH7.4, 1mM ethylene diamine tetraacetic acid (EDTA), 50mM NaCl and 0.5% Triton X-
100 with a protease inhibitor cocktail (Roche: 11836145001)),  for 3-4 hours at 4
o
C. For 
detecting phosphorylated proteins, phosphatase inhibitors, 1mM sodium orthovanadate 
(Sigma: S6508) and 5mM sodium fluoride (Sigma: S7920) would be added to the lysis 
buffer.  The cell lysate was then centrifuged at 13,000g, 4
o
C for 15 minutes and the 
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cleared lysate was then collected. Protein concentration was determined via the Biorad 
protein assay reagent (Bio-Rad: 500-0006).  
 
Tissue from rat were harvested according to the approved protocol and and lyzed 
with lysis buffer (Tris-HCl, pH7.4, 10 mM EDTA, 150 mM NaCl, 1% Triton X-100 with 
a protease inhibitor cocktail (Roche: 11836145001)),  for 3-4 hours at 4
o
C. The tissue 
lysate was then centrifuged at 50,000rpm, 4
o
C for 45 minutes and the cleared lysate was 
then collected. Protein concentration was determined via the Biorad protein assay reagent. 
 
2.5.5 Affinity pull-down assay 
 
 The affinity pull-down assay is an in vitro method to test for protein-protein 
interaction. The minimal requirement for this assay is the availability of a tagged protein 
(which in this case, is Rab22B that was fused to GST), which will act as a bait to pull-
down its’ protein interacting partner. 
 
 To confirm protein-protein interaction, 20g of GST-tagged protein beads were 
added to 1mg of lysate and incubated at 4
o
C, overnight, with gentle agitation. The beads 
were then centrifuged at 3200g for 30 seconds and the supernatant was discarded. The 
beads were washed 3x with lysis buffer and followed by another 2x with lysis buffer 
without Triton X-100. After washing, the beads were resuspended in 20L lysis buffer 
and 5L of 5x SDS-Page loading buffer (250mM Tris-HCl, 10% sodium dodecyl 
sulphate (SDS), 30% glycerol, 0.5M dithiothreitol and 0.02% bromophenol blue, pH7.4). 
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The beads were then heated at 70
o
C for 15 minutes before subjected to SDS-PAGE in 




 Similarly, co-immunoprecipitation is also a method to verify protein-protein 
interactions, particularly, those that are formed in vivo. The protein-protein complex is 
usually ‘pulled down’ using an antibody against one of the protein in the complex and 
detected via Western immunoblot using a second antibody against another protein. 
 
 In brief, 2g of antibody was added to 1mg of lysate and incubated at 4oC, 
overnight. Protein A (Amersham Biosciences: 17-5280-04) or Protein G (Amersham 
Biosciences: 17-0618-02) beads were added the next day. These proteins were isolated 
from the bacteria Staphylococcus aureus and immobilized on sepharose beads. Each 
protein has binding affinity for different species (Protein A recognizing antibodies raised 
in rabbits and Protein G recognizing antibodies raised in mice.).  The lysate with 
antibodies and beads were further incubated at 4
o
C, overnight with gentle mixing. The 
beads were washed as described in Section 2.5.3 before subjecting to SDS-PAGE and 
Western immunoblot. 
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2.5.7 Western immunoblot 
 
Western immunoblot was performed in detect a specific protein in a lysate, 
‘pulled-down’ materials from affinity pull-down assay, or immunoprecipitates. 
 
 Typically, for detecting a specific protein in a lysate, 50-100μg of total protein 
from the lysate would be loaded in a SDS-PAGE. For detecting a ‘pulled-down’ protein 
from affinity pull-down assay or co-immunoprecipitation assay, half or all the ‘pulled-
down’ proteins would be loaded. 
 
 In brief, upon loading the proteins in wells of an appropriate percentage SDS-
PAGE, the proteins would be electrophoresced at a constant voltage of 150V for 75 
minutes (Bio-Rad: 041BR, Bio-Rad Basic Power Pac). Thereafter, the proteins were 
electroblotted onto a nitrocellulose membrane (Amersham Biosciences: RPN203D). 
After immobilizing the proteins onto a nitrocellulose membrane, the membrane was 
blocked with 3% milk in Tris-buffered saline (TBS: 20mM Tris-HCl and 150mM NaCl, 
pH7.4) at room temperature for 60 minutes before probing with the respective antibodies 
in the cold room, overnight. The next day, the membrane was washed with TBS + 0.05% 
Tween-20 for three times before the addition of respective secondary antibodies 
conjugated with horse-radish peroxidase (HRP) (Thermo Scientific: 31430 (anti-mouse) 
or 31460 (anti-rabbit)). The secondary antibodies were incubated at room temperature for 
60 minutes. The membrane was washed again for three times with TBS + 0.05% Tween-
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20. Substrate (Thermo Scientific: 34080) was added and typically, film was exposed for 1 
minute for optimal band intensity. 
2.5.8 MTS assay 
The CellTiter 96
®
 AQueous Non-Radioactive Cell Proliferation Assay (Promega: 
G5421) is used in the course of this study to measure rate of cell proliferation. This assay 
uses the novel soluble tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-5- (3-
carboxymethoxyphenyl)-2 -(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) and the 
electron coupling reagent, phenazine methosulfate (PMS). MTS is chemically reduced by 
cells into formazan by dehydrogenase enzymes found in metabolically active cells. 
Formazan, which is soluble in tissue culture medium, causes the culture medium to 
change into an orange-brown color.  The intensity of the orange-brown color can be 
carried out using 96-well microplate at 490nm. Since dehydrogenase enzyme activity is 
found only in metabolically active cells, the production of formazan is proportional to the 
number of living and healthy cells. Thus, the intensity of the produced color is a good 
indication of cell number and viability of the cells.  
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2.6 Animal immunization and antibody production 
 
Fig. 2.7: Schematic diagram showing the process of animal immunization and antibody 
production.  
 
To create a specific antibody against Rab22B and avoid cross-reactivity with 
Rab22A, a GST-tagged fusion protein of the C-terminus end of Rab22B (amino acid 157-
195) (GST::Rab22B-C’) was used as the antigen for immunizing the rabbits (New 
Zealand White, Laboratory Animals Centre, Singapore). 500g of the fusion protein 
dissolved in PBS was combined with an equal volume of the appropriate adjuvant 
(Complete Freund’s Adjuvant for the first immunization followed by Incomplete 
Freund’s Adjuvant for all subsequent injections). The antigen and adjuvant were mixed 
Rab22B  
antibodies 
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thoroughly to form a stable emulsion using a syringe homogenizer. The emulsion was 
then injected subcutaneously (underneath skin at hind legs and back of the rabbits). After 
four booster injections, the blood is collected from the central ear artery with a 20-gauge 
injection needle (BD Biosciences: 305175) and allowed to clot at 4°C overnight. The 
clotted blood was clarified by centrifugation at 2000g for 20 minutes. The serum was 
collected, diluted 1:1 with PBS, and incubated with nitrocellulose strips with the 
immunogen immobilized by electroblotting. Bound antibodies were eluted from the strips 
using IgG elution buffer (Thermo Scientific: 21004).  
 
2.7 Statistical analysis 
 
 Experiments were usually repeated at least three times and statistical data analysis 
was conducted. Statistical data analysis was performed to avoid making conclusions 
based on one’s intuitive sense of significance. A Student’s T-test is usually performed to 
compare if the observed difference between the control and the test group is significant. 
As the Student’s T-test takes into account the sample size and the variation between each 
data point, it eliminates the chance that the observed difference between the control and 
test group is due to a lack of samples in each/either group and/or large variations in the 
each/either group is coincidental. P-value was calculated by using a formula embedded in 
Microsoft Excel.  
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3 Results and discussions 
 





The human Rab22B/Rab31 gene was first cloned in 1996 (Chen et al., 1996) and 
is localized to chromosome 18 (18p11.3) in the human genome (chromosome 17 (17 E1.1) 
of mouse). However, the precise cellular and tissue localization of endogenous Rab22B 
was never defined as a specific antibody against Rab22B was not available. A specific 
antibody will not only provide us with a handle to determine its’ cellular and tissue 
localization, it can also help in identifying interacting proteins that may help to delineate 
Rab22B’s role in vesicular trafficking.  
 
 To further understand the role that Rab22B may play in cellular trafficking, I 
sought to generate a specific antibody against Rab22B. Amongst the members in the Rab 
family, Rab22B has an exceptionally high sequence homology with the paralogous 
Rab22A, which resides on chromosome 20 (Fig. 3.1). To avoid cross-reactivity with 
Rab22A, which is apparently also found in the brain (Olkkonen et al, 1993), a region with 
the highest divergence between the two Rabs, namely the last 37 amino acids in the C-
terminus (Fig. 3.1), was fused to GST in a GST expression vector and expressed as a 
GST-fusion protein, GST::Rab22B-C’. This fusion protein was used as the antigen in the 
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immunization protocol. Serum collected from the rabbit was affinity-purified with the 





Fig. 3.1: Alignment of human Rab22A and Rab22B amino acid sequences. Pink highlight 
marks same amino acid. The red box indicates region of the highest divergence.  
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The affinity-purified rabbit anti-Rab22b antibody detected, by Western 
immunblot blot analysis, a band of ~ 21 kDa in HEK293 cells transfected with a myc-
tagged mammalian expression construct of Rab22B, but not cells transfected with 
Rab22A (Fig. 3.2)
1
. A similar result was also obtained via immunofluorescence analysis. 
Fluorescence signals were only detected for endogenous Rab22B (perinuclear staining) 
and the over-expressed Rab22B wild-type (WT) protein (but not Rab22A WT protein) in 
HeLa cells (Fig. 3.3).  
 
A band of ~20 kDa in size was also detected in a Western immunoblot survey of 
several rat tissues. The tissue survey confirmed that Rab22B is enriched in the brain (Fig. 
3.4). However, Rab22B proteins were also detected at comparable levels in the spleen 
and intestine and at much lower to undetectable levels in other organs. A developmental 
stage survey of the rat brain by immunoblot analysis indicated Rab22B’s presence at 
several stages of rodent embryonic and postnatal brain development (Fig. 3.5). 
                                                
1
 The larger size of the myc-tagged protein is apparently due to the myc epitope, which is 10 amino acids in 
length. It should also be noted that Rab22B is expressed in 293 cells, albeit at a lower level. The exposure 
condition used for this blot does not allow for the detection endogenous Rab22B in 293 cells. 




                    
Fig. 3.2: Rab22B antibody is specific and does not cross reacts with Rab22A. Upper 
panel: 293 cells were transfected with myc-tagged expression construct of Rab22A and 
Rab22B. Lysates were resolved on SDS-PAGE and subjected to Western immunoblot 
analysis with the Rab22B specific antibody. -tubulin was also probed to indicate protein 
loading for each lane. Lower panel: The blot was stripped and re-probed with myc 
antibody to confirm the expression of the both myc-tagged proteins. 
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Fig. 3.3: Rab22B antibody is specific and does not cross reacts with Rab22A. HeLa were 
transfected with either myc-tagged Rab22B (upper panel) or Rab22A (lower panel) and 
after 24 hours, cells were fixed for immunofluorescence analysis with Rab22B and myc 
antibodies, followed by FITC-conjugated donkey anti-rabbit Ig and Texas-red-conjugated 
donkey anti-mouse Ig. Bar = 10m. 
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Fig. 3.4: Rab22B protein is enriched in the brain. 100μg protein from rat tissues (brain, 
skeletal muscle, heart, liver, spleen, kidney and intestine) were loaded and subjected to 
immunoblot analysis using Rab22B antibody. The same blot was stripped and reprobed 
with an antibody against -tubulin to indicate the amount of protein loaded. Note: that 
intestine was analyzed on a separate Western immunoblot with identical amount of 





Fig. 3.5: Rab22B protein is present in embryonic and post-natal brain development. 
100μg of protein from rat brain lysates at embryonic days (E) 14, 16, 18, 20 as well as 
from newborn (NB) and young adults were subjected to Western immunoblot analysis 
using Rab22B antibody as above. -tubulin is to indicate the amount of protein loaded. 
Molecular size markings are in kDa. 
Results & discussions: Generation of a specific antibody against Rab22B and tissue distribution of Rab22B 
65 
  Discussion 
 
 In the large family of Rab GTPases with over 60 members in the human genome 
(Pereira-Leal, 2001), Rab22A and Rab22B form a cluster with the Rab5 paralogues and 
Rab21. Overall, Rab22B is about 70% identical to Rab22A (Fig. 3.1), but their C-
terminal hypervariable regions are rather divergent. Therefore, to avoid cross-reactivity 
with Rab22A, I have raised antibodies that are specific to the hypervariable region of 
Rab22B.  
 
Using assays such as the Western immunoblot and immunofluorescence analysis, 
I verified that the polyclonal antibodies generated against Rab22B are specific and do not 
cross-react with Rab22A (Fig. 3.2 and 3.3). The antibodies are, therefore, a critical tool, 
as the conclusions made in this study were based on assessing the effects of over-
expressing Rab22B or the depletion of endogenous Rab22B using siRNA.  
 
 Using these antibodies, it was established that Rab22B is enriched in the brain and 
two other tissues, the spleen and intestine (Fig. 3.4). It may also be present at low to 
undetectable levels in other tissues. Based on the intensity of the tubulin bands, it appears 
that Rab22B may be more enriched in the spleen and intestine. One of the reason could 
be these tissues are enriched in epithelial cells, which originate from the same germ layer 
(the ectoderm) as the brain. Another probable reason is that these tissues may have 
specialized secretory functions, such as secretion of immune components in the spleen 
and intestinal enzymes to aid digestion in the intestine, which could be regulated by 
Results & discussions: Generation of a specific antibody against Rab22B and tissue distribution of Rab22B 
66 
Rab22B. Rab22B’s role in the regulation of exocytosis at the TGN would be discussed in 
Section 3.4. It was also demonstrated that Rab22B is present during embryonic, post-
natal brain development and in the adult brain (Fig. 3.5). I have also shown that Rab22B 
is present at low levels during early embryonic (E14-16) brain development. The levels 
seemed to increase during late embryonic (E18-20) brain development. It was also 
observed that the level of Rab22B remains high till adulthood. At this juncture, it is not 
clear if the differences in the levels of Rab22B at different stages of brain development 
reflect its’ role in brain development. This issue will be further explored in the 
concluding section of my thesis.  
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 In the previous section, Rab22B was confirmed to be enriched in the brain. 
However, neither RNA in situ nor immunohistochemical data were available for Rab22B, 
and the cellular distribution pattern in the CNS is, therefore, unknown. When IHC 
analysis was performed using cryosections of fetal mouse brain, Rab22B-specific 
labeling, which is completely blocked by excess antigen (Fig. 3.6) and a good amount of 
Rab22B-specific labeling is found in nestin (neural progenitor cell marker)-positive and 
RC2 (radial glia marker) -positive but not A2B5 (neuronal and oligodendrocyte marker)-
positive fibers and cell bodies (Fig. 3.7). The morphological characteristics and marker 
specificity of these cells indicate that these are radial glia. The absence of Rab22B in 
A2B5 positive cells indicates that Rab22B is not detectable in oligodendrocyte/neuronal 
precursors. As shown in Fig. 3.8, observable overall Rab22B staining diminished in late 
embryonic (E18) and newborn mice, and Rab22B positive fibers observed at these stages 
are nestin but not yet glial fibrillary acidic protein (GFAP)-positive. 






















Fig. 3.6: Specificity of Rab22B labeling in brain sections – antigen blocking. 2μg of 
Rab22B antibodies were incubated with 20μg of GST::Rab22B-C’ recombinant protein 
before adding into 100μL of blocking buffer for incubation with cryosections from adult 
mouse brain, followed by incubation with FITC-conjugated donkey anti-rabbit Ig. Bar = 
20μm. 
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Fig. 3.7: Rab22B labeling in embryonic mouse brain. Cryosections from fetal mouse 
brain were obtained from E14 mouse and co-labeled with antibodies against Rab22B and 
RC2, nestin or A2B5, followed by FITC-conjugated donkey anti-rabbit Ig and Texas red-












Fig. 3.8: Rab22B staining at late embryonic stage. Cryosections from E18 mouse brain 
were obtained and co-labeled with antibodies against Rab22B and nestin or GFAP, 
followed by FITC-conjugated donkey anti-rabbit Ig and Texas red-conjugated donkey 
anti-mouse Ig. Bar = 20μm. 
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In the adult mouse brain, a good amount of Rab22B-specific staining is found 
almost exclusively in GFAP-positive astrocytes at several regions (Fig. 3.9). Rab22B 
immunoreactivity was not detected in either III-tubulin (TuJ)-positive neuronal cell 
bodies or CNPase-positive mature oligodendrocytes (Fig. 3.10). While Rab22B and 
GFAP showed extensive co-localization in astrocytes (lower panel, Fig. 3.10), Rab22B 
labeling was more confined to the cell body and not found in the astrocytic processes, 
unlike that of GFAP.  
 
To confirm the observations made with the brain cryosections, primary mixed 
glial cultures and astrocytes culture were prepared and immunocytochemistry analysis 
was performed. For the mixed glial cultures, CNPase-positive oligodendrocytes exhibited 
far weaker Rab22B’s staining compared to GFAP-positive astrocytes. As in the 
immunohistochemistry analysis, Rab22B’s signals in cultured astrocytes were more 
restricted to the perinuclear region while GFAP’s signals were more extensive, with 
signals extending to almost the end of each astrocytic process (Fig. 3.11).  
 
 




Fig. 3.9: Rab22B is present in the GFAP-positive astrocytes of different regions of the 
adult mouse brain. Cryosections from various regions of an adult mouse brain (midbrain, 
cortex, hippocampus, cerebellum, lateral ventricle and corpus callosum) were co-labeled 
with Rab22B antibody and a mouse monoclonal antibody against the astrocyte marker 
glial fibrillary acidic protein (GFAP). This is followed by FITC-conjugated donkey anti-
rabbit Ig and Texas red-conjugated donkey anti-mouse Ig. Bar = 20μm. 
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Fig. 3.10: Rab22B is expressed mainly in GFAP-positive astrocytes in the adult mouse 
brain. Cryosections from an adult mouse brain were co-labeled with Rab22B antibody 
and either a mouse monoclonal antibody against the neuronal marker, III-tubulin (TuJ), 
the oligodendrocyte marker, CNPase (2,3-cyclic nucleotide 3-phosphodiesterase), or the 
astrocyte marker glial fibrillary acidic protein (GFAP), followed by FITC-conjugated 
donkey anti-rabbit Ig and Texas red-conjugated donkey anti-mouse Ig. Bar = 20μm. 
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Fig. 3.11: Rab22B staining of primary astrocytes and oligodendrocytes in culture. Pure 
astrocytic cultures and mixed glial cultures were cultured from brains of post-natal (P) 1-
2 days old rat pups and cultured. Cultures were fixed and then labeled with antibodies 
against Rab22B and GFAP or CNPase, followed by FITC-conjugated donkey anti-rabbit 
Ig and Texas red-conjugated donkey anti-mouse Ig. Bar = 10μm. 




 Immunohistochemistry analysis with specific antibodies against Rab22B revealed 
an interesting distribution pattern in the brain. In earlier embryonic stage of E14-16, 
Rab22B is found in nestin and RC2-positive radial glia (Fig. 3.7). Historically, radial glia 
had been viewed primarily as migratory scaffolds and glial progenitors (Rakic, 2003). 
However, based on many recent in vitro studies and in vivo fate mapping work, it is now 
clear that the radial glia could in fact divide asymmetrically and give rise not only to 
astrocytes but neurons as well, during embryonic development (Gotz and Barde, 2005; 
Mori et al., 2005; Pinto and Gotz, 2007). 
 
 The IHC analysis in this section seemed to show that Rab22B’s staining 
diminishes at late embryonic stage (E18) (Fig. 3.8), which seemed to contradict the 
developmental Western blot analysis from the previous section (Fig. 3.5). Therefore, 
more analysis for the brain cryo-sections, for example, cryo-sections from different 
sections of the brain should be analyzed before a conclusion can be made as the current 
analysis is based on only a couple of cryo-sections from the same section of the brain and 
is focused on the cortical regions on the brain. 
 
 In the adult rodent brain, Rab22B is found to be exclusively expressed in GFAP-
positive astrocytes (Fig. 3.9). In following the expression pattern of Rab22B throughout 
embryonic and postnatal development, it appears that Rab22B in the brain is rather 
exclusively expressed in the astrocytic lineage, with low to undetectable expression in 
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either oligodendroglia or neuronal precursors or their respective matured counterparts. 
Though immunohischemistry analysis did not detect any clear Rab22B signals in these 
cells, low levels of Rab22B expression in these other cells could, however, not be ruled 
out.  
 
The lack of distinct staining for Rab22B in oligodendrocytes (Fig. 3.10 and 3.11) 
is seemingly at odds with a previous report indicating that Rab22B is specifically 
enriched in this particular cell type (Burcelin et al., 1997; Rodriguez-Gabin et al., 2001). 
A couple of reasons could explain the lack of Rab22B’s signals in the 
immunofluorescence analysis. One reason is that there is a much lower number of 
oligodendrocytes (when compared to the astrocytes in the brain) and my focus is on the 
cortical regions, which is the gray matter of the brain and oligodendrocytes are found 
mostly in the white matter. Secondly, the cytoplasmic volume of mature oligodendrocyte 
when compared to the astrocyte, are distinctly larger. Thus, there might be an 
intensification of Rab22B’s signals in astrocytes and a dilution of Rab22B’s signals in 
oligodendrocytes. Alternatively, previous analysis of Rab22B/Rab31 transcript levels had 
used oligodendroglia cultures that were mixed with astrocytes (the latter may have been a 
major contaminant of any crude oligodendrocyte preparations).  
 
At this moment, the exact physiological role for Rab22B in radial glia and 
astrocytes remained unclear, but it would be discussed and speculated in the concluding 
section of my thesis as the functions of Rab22B start to unravel. 
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 To determine Rab22B’s sub-cellular distribution and the potential role in 
trafficking, I would need a cell line that has an abundance of Rab22B and has various 
trafficking assays established. HeLa was chosen as a proxy for these studies because as 
indicated in Fig. 3.12, it has a reasonably high endogenous level of Rab22B and more 
importantly, various trafficking assays had already been established in HeLa.  
 
Other brain-derived cell line such as U87 (human glioblastoma cell line), OLN93, 
and 158N (rat and mouse oligodendroglial cell line, respectively) also had abundance 




 lanes from left). However, due to 
the lack of established markers and irregular cell morphology, they were not used in 
trafficking assays. 
 




Fig. 3.12: Rab22B expression status in various cell lines. 100 μg of lysates from different 
cell lines (U87, OLN93, 158N, HeLa) were subjected to immunoblot analysis using 
Rab22B antibody.  
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In a previous report by Rodriguez-Gabin et al., 2001, the cellular dynamics of the 
enhanced yellow fluorescent protein (EYFP)-tagged Rab22B in HeLa cells was followed. 
The relatively large fluorescent protein tag had been reported to change the sub-cellular 
distribution of some proteins (Palmer and Freeman, 2004). Therefore, I sought to 
determine the localization pattern of endogenous Rab22B. Prelimary analysis in HeLa 
cells using the Rab22B-specific antibodies showed staining of the perinuclear region and 
a good amount of endosomal-like staining (Fig. 3.13).  
 
 
The perinuclear stainings of Rab22B are characteristic of Golgi/TGN’s membrane 
stainings. Double-labeling of HeLa cells with antibodies against Rab22B and  TGN46 
and GM130, which are markers for the TGN and cis-Golgi, confirmed that the 
perinuclear staining of Rab22B  indeed show a substantial degree of co-localization with 
membranes of the TGN and the cis-Golgi (Fig. 3.14). 





Fig. 3.13: Rab22B’s staining in the preinuclear region is typical of the Golgi/TGN’s 
staining. HeLa cells were cultured and fixed for immunofluorescence analysis with 
Rab22B antibodies, followed by FITC-conjugated donkey anti-rabbit Ig. Bar = 10μm. 
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Fig. 3.14: Rab22B’s perinuclear staining shows a substantial co-localization with TGN46 
and GM130
2
. HeLa cells were cultured and fixed for immunofluorescence analysis with 
Rab22B and TGN46 or GM130 antibodies, followed by FITC-conjugated donkey anti-










 In Fig. 3.14, most of the cells in the second panel have nuclear background as compared to cells in the 
first panel. This is a common feature in some of the images presented in this thesis. One of the probable 
reason for this phenomenon is that the analysis were performed using different batches of antibodies and 
certain batches of antibodies do give a higher nuclear background as compared to other batches. Another 
common feature that is seen in this thesis is the endosomal-like staining observed in most images. My 
analysis had shown that these stainings do not co-localize with early endosomal marker such as EEA1. 
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To further differentiate if Rab22B resides on the membranes of the cis-Golgi or 
TGN, nocodazole and brefeldin A (BFA) treatments were performed. Nocodazole is a 
microtubule disrupting drug and prolonged treatment with nocodazole results in 
fragmentation of the Golgi and TGN. This is due to nocodazole binding to -tubulin and 
preventing formation of one of the two interchain disulfide linkages, thus inhibiting 
microtubule dynamics and destabilizes the Golgi stacks (Vasquez et al., 1997; Storrie et 
al., 1998). On the other hand, BFA inhibits GDP-GTP exchange of another GTPase, Arf1, 
which is involved in the recruitment of coat proteins required for the endoplasmic 
reticulum (ER) to Golgi transport (Klausner et al., 1992). Thus, BFA treatment blocks the 
transfer of coat proteins from the endoplasmic reticulum to the Golgi, resulting in the cis-
Golgi fragmenting into small, spotty structures and the TGN to a microtubule organizing 
center (MTOC)-like structure. 
 
Treatment of HeLa cells with nocodazole caused a majority of the perinuclear 
staining of Rab22B to fragment into small membranous islets that are positive for TGN46 
and GM130 (Fig. 3.15). This indicates that Rab22B is indeed localized on the membranes 
of the Golgi and/or TGN. 
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Fig. 3.15: Rab22B’s staining fragments into small membranous islands positive for 
TGN46 and GM130 upon nocodazole treatment. HeLa cells were cultured and treated 
with 10g/L of nocodazole, 37oC/60 minutes before fixing for immunofluorescence 
analysis with Rab22B and TGN46 or GM130 antibodies, followed by FITC-conjugated 
donkey anti-rabbit Ig and Texas-red-conjugated donkey anti-sheep or anti-mouse Ig. Bar 
= 10μm. 
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To further differentiate if Rab22B is on the Golgi’s membranes or the TGN’s 
membranes, HeLa cells was subjected to BFA treatment. Upon BFA treatment, it was 
observed that the TGN (marked by TGN46) did collapse into a more compact MTOC-
like structure and the cis-Golgi (marked by GM130) was dispersed into numerous small 
spotty structures. However, the staining of Rab22B did not follow the fate any of the 
markers but had instead become almost completely spotty (Fig. 3.16). Rab22B’s 
membrane association with either the Golgi or the TGN is, therefore, apparently sensitive 
to BFA treatment.  
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Fig. 3.16: Rab22B’s membrane association is sensitive to BFA treatment. HeLa cells 
were cultured and treated with 10g/L of BFA, 37oC/60 minutes before fixing for 
immunofluorescence analysis with Rab22B and TGN46 or GM130 antibodies, followed 
by FITC-conjugated donkey anti-rabbit Ig and Texas-red-conjugated donkey anti-sheep 
or anti-mouse Ig. Bar = 10μm. 




 Through Western immunoblot analysis of various cell lines, it was noted that 
besides being enriched in neural cell type-derived cell lines, Rab22B is also enriched in 
HeLa, a human cervical carcinoma cell line (Fig. 3.12). The presence of Rab22B in non-
astrocytic cell lines (U87, 158N and OLN97) and a non-neuronal cell line (HeLa) seemed 
to contradict the observations presented in the previous section (Section 3.2). Therefore, I 
would like to emphasize that in the previous section, observations were made in primary, 
non-transformed tissue sections and cells. In tumorigenic cell lines, such as those that 
were used in this Western immunoblot analysis, often had up-regulation of various 
regulatory genes. The up-regulation of some of these genes could indirectly/directly lead 
to an increase of other genes in the transcriptome, one of which may be Rab22B. 
 
Detailed immunocytochemistry analysis of the subcellular localization of Rab22B 
in HeLa cells indicates that the majority of Rab22B is localized to the perinuclear region, 
co-localizing with Golgi and TGN markers (Fig. 3.13 and 3.14). However, at the moment, 
it is difficult to clearly distinguish or quantify if Rab22B is more concentrated on the 
Golgi stacks or TGN membranes as BFA treatment dissociates Rab22B from these 
membranes (Fig. 3.16). This phenomenon is reminiscent of the response to BFA by 
another well-established Golgi/TGN Rab GTPase, Rab6 (Roa et al., 1993) 
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Since Rab22B’s is localized to the Golgi-TGN membranes, it is likely to be 
involved in membrane transport processes in and/or out of the Golgi. Investigations along 
this line are described in the next section.  
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A previous report had mentioned that tubulo-vesicular structures containing 
rRab22B::EYFP could be seen emanating from the TGN to endosomal structures.  
Intriguingly, the formation of these structures from the trans-Golgi was not observed 
when a Rab22B SN mutant was over-expressed (Rodriguez-Gabin et al., 2001). My 
findings describe above with regards to the Golgi/TGN localization of endogenous 
Rab22B also prompted me to investigate the effect of over-expressing its GTP-binding 
defective dominant negative mutant on Golgi and TGN markers. The investigations in 
this regard were focused on a mutant of Rab22B that is defective in GTP-binding, 
Rab22B S20N (Rab22B SN). Another possible mutant that could be examined would be 
Rab22B Q65L (Rab22B QL), of which corresponding mutations in other Rab proteins 
(such as Rab1 and Rab 5) had been shown to abolish their intrinsic GTPase activity, 
leaving them in a constitutively GTP-bound state. However, previous studies had shown 
that the Q-L mutation for Rab22B did not abolish its GTPase activity (Bao et al., 2002), 
thus, the effect of Rab22B QL on marker protein dynamics was not specifically examined. 
Investigations were carried out to assess if cells over-expressing the SN mutant of 
Rab22B will exhibit features or differences in trafficking pathways compared to 
overexpression of the wild-type (WT) protein.  
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 While overexpression of Rab22B WT protein had none or minimal disruption to 
the dynamic marker, TGN46, which cycles between the TGN and plasma membrane via 
the endosomes (Fig. 3.17, first panel), the overexpression of the mutant form of Rab22B, 
Rab22B SN, significantly disrupted TGN46’s staining (a change or loss of TGN46’s 
staining) (Fig. 3.17, second panel). Interestingly, the degree of disruption to TGN46’s 
staining was proportional to the level of transgene expression (Fig. 3.17, last panel; 
Arrowhead indicating cell with lower expression, less disruption and arrow indicating 
cell with higher expression, more disruption). A semi-quantitative scoring of the TGN’s 
staining disruption was performed, and the observed difference between cells over-
expressing Rab22B WT and Rab22B SN was statistically significant (p<0.01) (Fig. 3.18).  
 
I sought to further determine if the disruption of TGN46’s staining by Rab22B SN 
was cargo marker specific (ie. peculiar to only TGN46), or if it reflects a general 
disruption to all Golgi’membranes. In case of   the latter, all other Golgi markers would 
also be similarly affected. Overexpression of Rab22B SN , however, did not disrupt the 
staining of two other cis-Golgi markers, GM130 and Syntaxin 5 (Syn5) and a more static 
TGN marker, Syntaxin 16 (Syn16) (Fig. 3.19). Therefore, the effect of Rab22B SN on 
TGN’s dynamics appears to be rather specific for the dynamic marker TGN46.  
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Fig. 3.17: Rab22B SN protein disrupts TGN46’s staining. Rab22B WT or SN was over-
expressed in HeLa cells. Cells were fixed for immunofluorescence analysis after 16-18 
hours with Rab22B and TGN46 antibodies, followed by FITC-conjugated donkey anti-
rabbit Ig and Texas-red-conjugated donkey anti-sheep Ig. Note: Detection were adjusted 
to accommodate for the high amount of fluorescence emitted by over-expressing cells, 
therefore, endogenous Rab22B signals were not obvious. Bar = 10μm. 
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Fig. 3.18.: The observed difference in TGN46’s staining upon overexpression of Rab22B 
WT and SN protein is statistically significant. Bar indicates standard deviation. N= 73 
cells; **p<0.01.  
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Fig. 3.19: Rab22B SN on TGN’s dynamics appears is specific for the dynamic marker, 
TGN46. Rab22B SN was over-expressed in HeLa cells. Cells were fixed for 
immunofluorescence analysis after 16-18 hours with myc and GM130, Syn5 Syn16 
antibodies, followed by Texas-red-conjugated donkey anti-rabbit or anti-mouse Ig and 
FITC-conjugated donkey anti-mouse or anti-rabbit Ig. Bar = 10μm. 
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  Next, the Rab protein specificity of TGN46’s staining disruption was examined. 
As mentioned in Section 3.1, Rab22B shares an exceptionally high sequence homology 
with another Rab, Rab22A. When both Rab22A SN and Rab22B SN was over-expressed 
in HeLa cells, only the over-expression of Rab22B SN, but not Rab22A SN, disrupted 
TGN46’s staining (Fig. 3.20). 
 
Previous studies had reported that Rab22A is involved in the regulation of 
endosomal membrane traffic (Mesa et al., 2001; Kauppi et al., 2002; Weigert et al., 2005; 
Mesa et al., 2005).  To further illustrate the specificity of Rab22B SN’s disruptive effect 
on TGN46’s staining and its’ functional difference from Rab22A, the late endosomal 
membrane marker, mannose-6-phosphate receptor (M6PR) was examined. It was 
observed that the over-expression of Rab22A SN disrupted the staining of M6PR in HeLa 
cells and the overall staining of M6PR was diminished (Fig. 3.21). However, cells over-
expressing Rab22B SN had fairly intact M6PR staining. A semi-quantitative scoring of 
M6PR disruption was performed and the difference between Rab22A SN and Rab22B 
SN was statistically significant (p<0.001) (Fig. 3.22). 
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Fig. 3.20: Disruption to TGN46’s staining is specific to Rab22B SN. Rab22A/Rab22B SN 
were over-expressed in HeLa cells. Cells were fixed for immunofluorescence analysis 
with myc and TGN46 antibodies, followed FITC-conjugated donkey anti-rabbit and 
Texas red-conjugated donkey anti-sheep Ig. Bar = 10μm. 
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Fig. 3.21: Rab22B SN disrupts only TGN46’s staining, but not M6PR’s. Rab22A/Rab22B 
SN were over-expressed in HeLa cells. Cells were fixed for immunofluorescence analysis 
with myc and M6PR antibodies, followed Texas red-conjugated donkey anti-rabbit and 
FITC-conjugated donkey anti-mouse Ig. Bar = 10μm. 
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Fig. 3.22. The observed difference in M6PR’s staining upon overexpression of Rab22ASN 
and Rab22BSN is statistically significant. Bar indicates standard deviation. N= 445 cells; 
***p<0.001. 
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As Rab22A and Rab22B are highly homologous, the differences in the effect of 
their SN mutants on the markers examined are interesting. Therefore, I asked if the C-
terminal hypervariable region of Rab22B, which diverges from Rab22A, could be 
responsible for the Rab22B specific disruption of TGN46 staining. To do this, two myc-
tagged chimeric constructs, Rab22ANterRab22BCterSN and Rab22ACterRab22BNterSN (Fig. 
3.23) with C-terminal domain swaps, were generated. It was observed that only the 
chimera Rab22ANterRab22BCterSN (ie. Rab22A SN mutant with a Rab22B C-terminus) 
was able to disrupt TGN46’s staining (Fig. 3.24). A semi-quantitative scoring of the 
disruptive effect between the two chimeras was statistically significant (p<0.001) (Fig. 
3.25). 
 
While overexpressing a dominant negative protein cells is one way to inhibit the 
function of a target protein, the phenomenon seen upon over-expressing a dominant 
negative protein in cells can be influenced by non-specific gain-of-function properties of 
the mutant and the over-expressed protein binding non-specifically to other proteins. 
Thus, to corroborate our findings with Rab22B SN’s over-expression, the effect of 
depleting endogenous Rab22B on TGN46’s dynamics was investigated. The depletion 
was carried out by transfecting 27mer Dicer-ready siRNA (see Materials and methods) 
into HeLa cells.  
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Fig. 3.24: Only Rab22ANterRab22BCterSN was able to disrupt TGN46’s staining.  HeLa 
cells were cultured and transfected with the chimera constructs before being fixed for 
immunofluorescence analysis with myc (9E10) and TGN46 antibodies, followed FITC-
conjugated donkey anti-mouse and Texas red-conjugated donkey anti-sheep Ig. Bar = 
10μm. 




Fig. 3.25: The observed difference in TGN46’s staining upon over-expression of Rab22B 
SN/ Rab22ANter22BCter and Rab22ACter22BNter is statistically significant. Bar indicates 
standard deviation. N= 461cells; ***p<0.001.  
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 As Rab22B shares a high sequence homology with Rab22A, our choice of siRNA 
target region is limited. The gene silencing specificity of the siRNA was tested out by 
transfecting the siRNA into 293 cells stably expressing either myc-tagged Rab22A or 
myc-tagged Rab22B, and the silencing effect was assessed by Western immunoblot using 
anti-myc antibodies. The Rab22B siRNA efficiently silenced over-expressed myc-tagged 
Rab22B, but not myc-tagged Rab22A (Fig. 3.26). As shown in Fig. 3.27, Rab22B siRNA 
also efficiently silenced endogenous Rab22B in HeLa (by about 70%). 
 
Upon depletion of endogenous Rab22B in HeLa cells, it was noted that TGN46’s 
staining became diffused and diminished (Fig. 3.28). The difference in fluorescence 
intensity of TGN46 between non Rab22B-depleted and Rab22B-depleted cells was 
quantified using a program embedded in the confocal imaging software (LSM510, Carl 
Zeiss)  and the difference was statistically significant (p<0.001) (Fig. 3.29). 






Fig. 3.26. Rab22B siRNA is specific and efficiently silenced overexpression of myc-
tagged Rab22B but not myc-tagged Rab22A. 293 cells were stably expressing myc-
tagged Rab22A/Rab22B were transfected with Rab22B siRNA. Lysates were resolved by 
SDS-PAGE and subjected to immunoblot analysis with the myc antibody. -tubulin was 





Fig. 3.27: Rab22B siRNA effectively silenced endogenous Rab22B in HeLa. HeLa cells 
were cultured and transfected with Rab22B siRNA. After 48 hours, lysates were obtained 
and resolved on SDS-PAGE and subjected to immunoblot analysis with the Rab22B 
specific antibody. -tubulin was also probed to ensure equal loading.  
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Fig. 3.28: Depletion of endogenous Rab22B in HeLa cells changes and diminishes 
TGN46 staining. HeLa cells were cultured and transfected with Rab22B siRNA for 48 
hours. Cells were fixed for immunofluorescence analysis with Rab22B and TGN46 
antibodies, followed by FITC-conjugated donkey anti-rabbit and Texas red-conjugated 
donkey anti-sheep Ig after 48 hours. Bar = 10μm. 
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Fig. 3.29: The observed difference in TGN46’s fluorescence between non Rab22B-
depleted and Rab22B-depleted cells is statistically significant. Bar indicates standard 
deviation. N= 88; ***p<0.001. Using the software embedded in the imaging program 
(LSM 510), the Golgi region of each cell was marked and the amount of fluorescence in 
the Golgi region was quantitated by the software. 
 




 It was observed that Rab22B SN has a rather specific effect in disrupting the 
steady state localization of TGN dynamic marker, TGN46 (Fig. 3.17), but not those of the 
cis-Golgi marker syntaxin 5 or the more static TGN marker syntaxin 16 (Fig. 3.19). 
Besides disrupting TGN46, Rab22B SN also assumes a more perinuclear localization 
than the WT counterpart. While one does not expect the GTP-binding deficient mutant to 
bind to any effectors, it had been reported that the GTP-binding mutant can bind to 
proteins other than their effectors (Shirane and Nakayama, 2006). Thus, Rab22B SN may 
have bind to TGN proteins, which allows it to assume a more perinuclear localization.  
 
The specificity of this disruptive phenotype induced by the over-expression of 
Rab22B SN is further illustrated by the fact that TGN46 staining was not disrupted or 
perturbed when Rab22A SN, the close paralogue of Rab22B, that has been implicated in 
endosomal trafficking (Mesa et al., 2001; Kauppi et al., 2002; Weigert et al., 2005; Mesa 
et al., 2005), was over-expressed (Fig. 3.20) In contrast, the distribution of the late 
endosomal marker, M6PR, was not disrupted or perturbed by Rab22B SN (Fig. 3.21), but 
disrupted by Rab22A SN.  
 
 My prelimary analysis of another brain-enriched Rab GTPase, Rab40C, has 
revealed some intriguing similarities, as well as differences with Rab22B. Over-
expression of wild-type myc-tagged Rab40C WT, as well, as its mutants, also disrupted 
TGN46’s staining to similar extents (Appendix A, Fig. A1). Like Rab22B, Rab40C also 
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interacts with EEA1 in a GTP-dependent manner (to be discussed in Section 3.6) 
(Appendix A, Fig. A2.). However, unlike Rab22B which may play a role in anterograde 
transport (to be discussed in the next section), Rab40C over-expression disrupted 
transferrin trafficking (Appendix A, Fig. A3).  
 
 The specificity of Rab22B’s effect on TGN46 was revealed when only the 
chimera construct expressing the C-terminus end of Rab22B disrupts the staining of 
TGN46 (Fig. 3.24). Results from this domain swapping experiment not only 
demonstrates that Rab22B is indeed responsible for disrupting TGN46, it also 
demonstrates that the C-terminal hypervariable region could have a role in dynamic 
transport between the TGN and other post-Golgi compartments such as the cell surface. 
 
 As results from over-expression studies may suffer from possible gain-of-function 
effects, I assessed if TGN46 staining would be disrupted when endogenous Rab22B was 
depleted. As the sequence of Rab22A and Rab22B shares a high degree of homology, the 
specificity of Rab22B siRNA was confirmed (Fig. 3.26) before the assessment of TGN46 
staining. Interestingly, that while the knockdown of Rab22B protein did not generate an 
effect that is as drastic as when the Rab22B SN mutant is over-expressed, the staining of 
TGN46 was significantly changed and diminished (Fig. 3.28). Further analysis in the 
future should be carried out to determine if the diminished TGN46’s staining could also 
be due to mis-targteting of TGN46 or a defect in endosomal trafficking which could have 
been an indirect effect from a defect in TGN trafficking. Therefore, while these results 
seemed to indicate that Rab22B has a specific and rather confined function at the TGN, 
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as described in sections below, Rab22B may also have functions at cellular locations 
other than the TGN. 
Results & discussions: Rab22B’s role in TGN and post-Golgi traffic 
107 




 Rab22B’s localization at the Golgi/TGN’s membranes, in conjunction with the 
disruption of TGN46’s staining when Rab22B SN is over-expressed, suggests that 
Rab22B could be involved in membrane trafficking into and/or out of the TGN. A closer 
scrutinization of Rab22B’s staining pattern (Fig. 3.13) indicated that a minor fraction of 
Rab22B is also present in membranous structures that resemble endosomal compartments. 
This observation, in conjunction with earlier demonstration of dynamic Rab22B 
movement between TGN and endosomal structures (Rodriguez-Gabin et al., 2001) 
prompted me to check if Rab22B also plays a role in  TGN as well as post Golgi 
endocytic trafficking. 
 
 Firstly, it was observed that over-expression of Rab22B SN did not have any 
discernible effect on the endosome-TGN transport of Shiga B toxin (Fig. 3.30). 
Endocytosis of classical endocytic cargo tagged with fluorophores, such as transferrin-
FITC was also not significantly affected (Fig. 3.31). Since Rab22B SN’s overexpression 
did not affect retrograde transport of the Shiga B toxin and the staining pattern of M6PR 
(which shuttles between the late endosome and TGN) was also not affected (Fig. 3.32, 
see also Fig. 3.21 in section 3.4 above), this seemed to suggest that Rab22B’s role at the 
TGN may concern anterograde rather than retrograde transport.   
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Fig. 3.30: Over-expression of Rab22BSN does not affect endosome-TGN transport – 
Shiga B transport. Rab22B WT or SN was over-expressed in HeLa cells. Following 
transfection (after 16-18 hours), the cells were subjected to a 18
o
C incubation to 
internalize Shiga B toxin and a further incubation at 37
o
C for 60 minutes. Cells were then 
fixed for immunofluorescence analysis with Rab22B and Shiga antibodies, followed by 
FITC-conjugated donkey anti-rabbit and Texas red-conjugated donkey anti-mouse Ig. Bar 
= 10μm. 
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Fig. 3.31: Over-expression of Rab22BSN does not affect endocytosis – Tf trafficking. 
Rab22B WT or SN was over-expressed in HeLa cells. Following transfection (after 16-18 
hours), the cells were subjected to an 18
o
C incubation to internalize transferrin-FITC and 
a further incubation at 37
o
C for 10 minutes. Cells were then fixed for 
immunofluorescence analysis with Rab22B antibodies, followed by TxR-conjugated 
donkey anti-rabbit Ig. Bar = 10μm. 
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Fig. 3.32: Over-expression of Rab22BSN does not affect late endosomal-TGN trafficking 
–M6PR trafficking. Rab22B WT or SN was over-expressed in HeLa cells. Following 
transfection (after 16-18 hours), cells were then fixed for immunofluorescence analysis 
with Rab22B and M6PR antibodies, followed by TxR-conjugated donkey anti-rabbit and 
FITC-conjugated donkey anti-mouse Ig. Bar = 10μm. 
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To assess if Rab22B was indeed involved in anterograde trafficking out of the 
TGN, a construct expressing a classical anterograde transport cargo, the temperature-
sensitive mutant vesicular stomatitis viral glycoprotein (VSVGts045), was transfected 
into HeLa. The VSVGts045 protein expressed in this study is tagged to YFP and has a 
reversible temperature-sensitive mutation in the lumenal domain that inhibits proper 
folding and subsequent exit from the ER at the nonpermissive temperature of 40°C, but 
refolds at the permissive temperature of 32°C to allow exit of the protein.  
 
While cells overexpressing Rab22B WT has no observable effect on VSVG 
transport, cells overexpressing Rab22B SN protein exhibited an accumulation of 
VSVGts045 at the Golgi-TGN area (Fig. 3.33). Semi-quantitative scoring of Golgi-TGN 
entrapment of VSVGts045 in the cells showed that the effect induced by Rab22B SN is 
statistically significant (p<0.001) (Fig. 3.34).  
 
However, a similar degree of VSVGts045 entrapment was not observed when 
endogenous Rab22B was depleted. There seemed no noticeable difference in the export 
of VSVG between the cells treated with scrambled-control (Sc) and Rab22B siRNA (Si) 
(Fig. 3.35). 
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Fig. 3.33: Over-expression of Rab22BSN inhibits the export of VSVG cargo. Rab22B WT 
or SN was over-expressed in HeLa cells. Following transfection (after 16-18 hours), cells 
were first subjected to 39.5
o
C incubation for 40 minutes, followed by a shift to 32
o
C for 5 
hours. Cells were then fixed for immunofluorescence analysis with Rab22B and VSVG 
antibodies, followed by TxR-conjugated donkey anti-rabbit and FITC-conjugated donkey 
anti-mouse Ig. Arrows points to Golgi/TGN entrapment of VSVG. Arrowhead points to 
an untransfected cell. Bar = 10μm. 
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Fig. 3.34: The inhibition of VSVG cargo upon overexpressing Rab22B SN protein is 
statistically different
3




















Only compact perinuclear staining such as those shown in second panel of Fig. 3.33 were counted as 
cells with inhibited VSVG export. 




Fig. 3.35: Depletion of Rab22B does not inhibit export of VSVG cargo. HeLa cells were 
first transfected with scrambled-control (Sc) or Rab22B siRNA (Si). After 24 hours, cells 
were transfected with the VSVG expression construct. Cells were then first subjected to 
39.5
o
C incubation for 40 minutes, followed by a shift to 32
o
C for 5 hours before being 
fixed for immunofluorescence analysis with Rab22B and VSVG antibodies, followed by 
TxR-conjugated donkey anti-rabbit and FITC-conjugated donkey anti-mouse Ig. Bar = 
10μm. 
 




 The localization of Rab22B at the Golgi/TGN and the observation that over-
expression of the dominant negative Rab22B SN disrupts TGN46 localization suggest 
that Rab22B may be involved in trafficking processes in and/or out of the TGN. However, 
neither Shiga B retrograde transport from the early endosome to the TGN (Fig. 3.30), 
transferrin-trafficking from the early-recycling endosome (Fig. 3.31), nor the trafficking 
of M6PR, which shuttles between the late endosome and the TGN (Fig. 3.32), is affected 
by the over-expression of Rab22B SN. This further suggests that Rab22B’s role at the 
TGN may concern TGN anterograde transport rather than retrograde traffic.  
 
The possibility of Rab22B’s role in regulating TGN exit was confirmed by 
checking if the over-expression of Rab22B SN blocks the anterograde transport of the 
temperature-sensitive VSVG mutant. As shown in Fig. 3.33, the over-expression of 
Rab22B SN resulted in a significantly higher degree of VSVG accumulation or 
entrapment at the Golgi-TGN. The entrapment of VSVG cargoes appeared as a compact 
and bright perinuclear staining, and was morphologically distinct from the more diffuse 
VSVG labeling of internal membranes in transit to the cell surface as observed in 
Rab22B WT expressing cells. A semi-quantitative scoring indicated a very significant 
degree of entrapment associating with Rab22B SN expression compared to wild type 
(p<0.001, Fig. 3.34). Rab22B SN over-expression therefore appeared to rather 
specifically perturbed exit out of the TGN. 
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To further verify that Rab22B does indeed play a crucial role in TGN exit, 
endogenous Rab22B was depleted from HeLa cells before the export of VSVG was 
assessed. However, depletion of Rab22B did not seem to affect export of VSVG to the 
cell surface (Fig. 3.35). One possible reason for this observation is that there is functional 
redundancy in the machinery regulating TGN exit. Indeed, the results suggest Rab22B is 
probably not essential for general TGN exit. However, over-expressed Rab22B SN could 
still negatively affect TGN exit due to its effect on the TGN exit machinery. Therefore, 
while Rab22B may not be the main player in anterograde traffic, it may still function in 
concert with other proteins that are involved in anterograde exit out of TGN via the 
endosomes. This hypothesis is made in concert with observations that tubules carrying 
rRab22B-YFP were seen exiting the TGN and going towards endosomal structures 
(Rodriguez-Gabin et al., 2001).  Another probable reason is that the over-expression of a 
dominant negative mutant can also non-specifically bind to effectors of other Rab 
proteins involved in the same pathway. Lastly, another  important possibility to keep in 
mind would be that in some cell types (for example in astrocytes, in which Rab22B is 
particularly enriched in), the Rab protein may regulate the transport of some cargo in a 
cell-type specific manner. 
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 Recent findings that GAPex-5 (or GTPase-activating protein and VPS9 domain-
containing protein 1 (GAPVD1)) is a guanine nucleotide exchange factor for 
Rab22B/Rab31 (Lodhi et al., 2007). Another group has also reported that it mediates 
ubiquitination, trafficking and degradation of EGFR (Su et al., 2007). As shown in the 
section above, Rab22B SN did not affect transferrin uptake or Shiga B transport from the 
endosome to the TGN. Interestingly, immunofluorescnce analysis suggested that GAPex-
5 is co-enriched with Rab22B in astrocytes in the central nervous system (Fig. 3.36). This 
prompted me to examine Rab22B’s role in EGFR trafficking. Attempts made to assess 
the role of Rab22B in modulating EGFR trafficking in commercially-available 
astrocytoma cell lines were unsuccessful due to the lack of characterized markers in these 
cell lines and growth-associated problem. Therefore, A431, a skin carcinoma cell line, 
which is enriched with Rab22B and EGFR was used as a proxy to investigate Rab22B’s 
role in EGFR trafficking.  
 
 In this line of investigation, I had focused on the effect of Rab22B silencing. As 
shown in Fig. 3.37, Rab22B siRNA effectively silenced Rab22B expression to ~80% of 
that of a scrambled control RNA. The EGFR staining pattern between Rab22B siRNA 
treated cells were clearly different from that treated with scrambled control RNA 5 min 
after stimulation with EGF.  







Fig. 3.36: GAP-ex5 is co-enriched with Rab22B in astrocytes in the brain. Cryosections 
from adult mouse brain were co-labeled with polyclonal antibodies against Rab22B 
(generated by Monoclonal Antibody Unit, Institute of Molecular and Cell Biology) and 
GAPex-5 (generously provided by Prof. Alan Saltiel, University of Michigan), followed 
by FITC-conjugated donkey anti-mouse Ig and Texas red-conjugated donkey anti-rabbit 





Fig. 3.37: Rab22B siRNA effectively silenced endogenous Rab22B in A431. A431 cells 
were cultured and transfected with Rab22B siRNA. After 48 hours, lysates were obtained 
and resolved on SDS-PAGE and subjected to Western immunoblot analysis with the 
Rab22B specific antibody. -tubulin was also probe to ensure equal loading. Immunoblot 
presented is a representation of the efficiency of the silencing.  
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Internalization of EGFR appeared slower in Rab22B siRNA treated cells. Sixty 
minutes after stimulation with EGF, the EGFR staining patterns were even more 
distinctly different. EGFR of scrambled control RNA-treated cells were largely found in 
large punctate structures characteristic of those seen for untreated cells, while EGFR in 
Rab22B-silenced cells labels much finer spotty structures (Fig. 3.38). Similarly, EGF-
Texas Red internalized by Rab22B siRNA-treated cells were found in structures that are 
much smaller than scrambled control RNA-treated cells (Fig. 3.39). 
 
From the morphological features of the EGFR- and EGF-TxR containing 
structures, it appears that Rab22B silencing had prevented or delayed EGFR trafficking 
to late endosomal compartments. To confirm this hypothesis, double-labeling of A431 
cells with CD63, a late endosome/lysosome marker was performed. Sixty minutes after 
EGF-TxR stimulation, EGF-TxR in scrambled control RNA-treated cells were found in 
larger punctate structures that were also CD63-positive (Fig. 3.40, first panel). However, 
for Rab22B siRNA treated cells, EGF-TxR-containing structures were smaller and spotty 
and were largely negative for CD63 (Fig. 3.40, middle panel).  
 
To verify that GAPex-5 and Rab22B function along the same pathway, 
endogenous GAPex-5 was also depleted. GAPex-5 siRNA’s sequence was identical to 
that used in Su et al., 2007. GAPex-5 siRNA effectively silenced GAPex-5’s expression 
to about ~80% of that of a scrambled control RNA (Fig. 3.41). Likewise, EGF-TxR-
containing structures were smaller and spotty and were largely negative for CD63 when 
GAPex-5 was silenced (Fig. 3.40, lower panel). 
Results & discussions: Rab22B’s role in modulating EGFR trafficking and signaling 
120 
 
Fig. 3.38: Rab22B knockdown slows down the internalization of EGFR. A431 cells were 
transfected with scrambled control (Sc) or Rab22B (Rab22BSi) siRNA for 48 hours. 
Cells were serum-starved overnight, pulsed for 5 min with 100 ng/ml of EGF before a 
chase in complete medium for 60 min. Cells were then fixed and labeled with antibodies 
against EGFR (Upstate: 06-847), followed by Texas red-conjugated donkey anti-rabbit Ig. 
Bar = 10m. 
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Fig. 3.39: EGFR and EGF-TxR found in smaller, spotty structures upon Rab22B 
knockdown. A431 cells were transfected with scrambled control (Sc) or Rab22B 
(Rab22BSi) siRNA for 48 hours. Cells were serum-starved overnight, pulsed for 5 min 
with 200 ng/ml of EGF-TxR before a chase in complete medium for 60 min. Cells were 
fixed and labeled with antibodies against EGFR, followed by FITC-conjugated donkey 
anti-rabbit Ig. Bar = 10m. 
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Fig. 3.40: Rab22B and GAP-ex5 silencing prevent the trafficking of EGFR/EGF-TxR into 
the late endosomal/lysosomal compartments. A431 cells were transfected with either a 
scrambled control RNA (Sc) (top panel) or Rab22B (Rab22BSi) (middle panel) or 
GAPex-5 (GAPex-5Si) (lower panel) siRNA for 48 hours. Cells were serum starved 
overnight, pulsed for 5 min with 200 ng/ml of EGF-TxR before a chase in complete 
medium for 60 minutes. Cells were then fixed and labeled with antibodies against CD63, 
followed by FITC-conjugated anti-mouse Ig. The right panels are magnified from parts 
bracketed by the white squares. Arrows point to punctate structures with positive for both 
EGF-TxR and CD63 in cells transfected with scrambled control RNA. Arrowheads point 
to EGF-TxR containing structures that are CD63 negative in cells transfected with 
Rab22B or GAPex-5 siRNA. Bar = 10m. 




Fig. 3.41: GAPex-5 siRNA effectively silenced endogenous GAPex-5 in A431. A431 cells 
were cultured and transfected with GAPex-5 siRNA. After 48 hours, lysates were 
obtained and resolved on SDS-PAGE and subjected to Western immunoblot analysis 
with the GAPex-5 specific antibody. -tubulin was also probe to ensure equal loading. 
Immunoblot presented is a representation of the efficiency of the silencing.  
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Both Rab22B and GAPex-5 silencing therefore resulted in the inhibition of EGFR 
transport into CD63-positive late endosomal/lysosomal compartments. 
 
 To explore the possible underlying mechanistic basis for Rab22B’s influence on 
EGFR transport, assays were carried to assess if Rab22B could actually associate with 
EGFR. As shown in Fig. 3.42, although beads carrying glutathione S-transferase (GST) 
alone bind a certain amount of EGFR, GST-Rab22B fusion protein pulled down 
significantly more EGFR in the presence of GTPS, a non-hydrolyzable analogue of 
GTP, than in its absence. This indicates that the interaction the between GST-Rab22B 
and EGFR occurs in a GTP-dependent manner. EGFR also co-immunoprecipitated with 
Rab22B antibody in a GTPS-dependent manner, but did not co-precipitate with either 
Rab5 antibody or anti-myc antibody (9E10) in myc-tagged Rab22A transfected cells (Fig. 
3.43). 
 
As EGFR trafficking is closely tied to its signalling, I checked the 
phosphorylation of signalling intermediates downstream of EGFR, extracellular signal-
regulated kinase (ERK)1/2. Rab22B silencing did not appear to affect magnitude or 
kinetics of the fast phosphorylation of ERK1/2. However, phosphorylation of ERK1/2 
appeared to have persisted for a longer period when monitored over 60 minutes in 
Rab22B-depleted cells compared to control (Fig. 3.44, boxed).  
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Fig. 3.42: GST-Rab22B can pull down EGFR in a GTP-dependent manner. 20μg of GST 
or GST::Rab22B recombinant protein beads were added to 1 mg of A431 lysate, and 
incubated for a few hours. Beads were then washed and bound proteins eluted with SDS-







Fig. 3.43: Rab22B co-immunoprecipitates with EGFR in a GTP-dependent manner in 
vivo. 3 μg of the respective antibodies (Rab22B, Rab5 and 9E10 (anti-myc)) were added 
to 1 mg of A431 lysate. The antibodies were incubated with the lysate, followed by 
addition of Protein A or G sepharose beads. Beads were then washed and bound proteins 
eluted with SDS-PAGE sample buffer, followed by Western immunoblot analysis with 
respective Rab/myc (upper panel) to confirm that the IP antibdodies can pull down the 
respective Rab proteins or EGFR antibodies (lower panel) to confirm the association of 
Rab22B and EGFR. 
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Fig. 3.44: Rab22B depletion slows down the dephosphorylation of ERK1/2. A431 cells 
were transfected with scrambled control (Sc) or Rab22B (Si) siRNA for 48 hours. Cells 
were then serum-starved before stimulation with 100ng/mL of EGF for the respective 
time-points. Upon stimulation, cells were lyzed for Western immunoblot analysis with 
antibodies against total ERK1/2 (Cell Signaling: 9107) and phosphorylated (phos.) 
ERK1/2 (Cell Signaling: 9101). Blot presented is a representative of three separate 
experiments.  
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I next asked if this more robust persistence in EGFR signalling (as reflected by 
prolonged ERK1/2 phosphorylation) could influence the proliferation rate of the cells. 
Interestingly, when monitored over 72 hours, proliferation (as indicated by MTS assay) 
was significantly increased in cells treated with Rab22B siRNA compared to scramble 
control RNA (Fig. 3.45). These data, taken together, suggest that Rab22B plays a role in 
EGFR traffic and could influence its signalling.   




Fig. 3.45: Rab22B depletion results in a change in proliferative rate of A431 cells. A431 
cells were transfected with either a scrambled control (Sc) or Rab22B (Rab22BSi) siRNA 
and cell proliferation was followed by the MTS assay (see Materials and Methods) at the 
respective time-points. p value of differences between Sc and Rab22BSi: **p<0.01. 
Graph shown is a representative of three independent experiments. 




 While the observation that Rab22B modulates EGFR trafficking in A431 is 
mildly surprising, it is nonetheless, intriguing. Firstly, Rab22B silencing did not affect 
transferrin endocytosis or Shiga toxin uptake (Fig. 3.46). Its effect on EGFR therefore 
appears rather specific, and this may be at least partially explained by Rab22B’s 
association with EGFR. The specificity of this association is likely high as it occurs in a 
GTP-dependent manner and Rab22A and Rab5, which had been reported to be involved 
in endocytosis and endocytosis of EGFR, respectively,  (Barbieri et al., 2000 and Mesa et 
al., 2004) did not seemed to associate with EGFR.  
 
Secondly, the main apparent membrane localization of Rab22B in both HeLa and 
A431 cells are both predominantly TGN rather than endosomal (Fig. 3.47). However, as 
demonstrated previously by Rodriguez-Gabin et al., 2001, Rab22B could shuttle between 
TGN and endosome. Another report had also shown that silencing of syntaxin 10, a 
TGN-localized SNARE molecule, perturbed transferrin receptor traffic (Wang et al., 
2005). A minor fraction of Rab22B that are localized to endosomal membranes (but not 
obvious via immunocytochemistry), particularly in cell types that the molecule is 
exceptionally enriched in, could well have important and discernible roles in EGFR 
transport. Therefore, in this regard, it is also worth noting that signaling from the EGFR 
plays important roles in astrocyte differentiation during development, as well as astrocyte 
activation during CNS injury (Liu et al., 2006 and Liu et al., 2007).  
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Fig. 3.46: Rab22B silencing does not affect the endocytic iternaries of transferrin and 
Shiga B toxin. Cells transfected with scrambled control (upper panels) or Rab22B 
(Rab22BSi) siRNA (lower panels) were incubated for 48 hours prior to FITC-transferrin 
uptake assay or Shiga toxin B uptake assay. Cells were incubated with 0.005 mg/ml of 
FITC-transferrin (left panels) or Shiga toxin B (right panels) at 18
o
C for 60 minutes and 
washed with chilled medium before the addition of pre-warmed complete medium. Cells 
were then further incubated for 10 mins (for FITC-transferrin) or 60 min (for Shiga toxin 
B) at 37
o
C before fixation for immunofluorescence analysis. Cells in Shiga toxin B 
uptake was labeled with an antibody against Shiga toxin B followed by Texas red-
conjugated donkey anti-mouse Ig. Bar = 10m. 
 




Fig. 3.47: Rab22B apparent membrane localization is at the TGN in HeLa and A431. 
HeLa and A431 cells were cultured and fixed for immunofluorescence analysis with 
Rab22B antibodies, followed by FITC-conjugated donkey anti-rabbit Ig. Bar = 10m.  
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In the adult neurogenic subventricular zone, conversion of quiescent astrocyte-
like cells to transit-amplifying neurogenic precursors coincide with increased EGFR 
expression and EGF signaling could convert these cells into multipotent progenitors cells 
(Doetsch et al., 2002). Although direct evidence is currently lacking, Rab22B that is 
enriched in astrocytes may have an important role in modulating EGFR trafficking and 
signaling. Furthermore, astrocytes are also apparently enriched in the Rab22B’s guanine 
nucleotide exchange factor, GAPex-5 (Fig. 3.36). 
 
Another plausible explanation for the effect of Rab22B silencing on EGFR 
trafficking stems from the fact that Rab22B shares common regulators with Rab5, e.g., 
GAPex-5 (Lodhi et al., 2007) and common effectors with the endocytic Rabs, Rab5 and 
Rab22A, e.g., the early endosomal antigen 1 (EEA1) (Lodhi et al., 2007; Christoforidis et 
al., 1999; Kauppi et al., 2002). Massive affinity pull-down assays indicate that Rab22B 
can pull down EEA1 and prelimary co-immunoprecipitation assay also indicates that 
Rab22B can co-immunoprecipitate EEA1 in a GTP-dependent manner (Fig. 3.48). 
Besides co-immunoprecpitation assays to show the association of Rab22B with EGFR 
and EEA1, immunocytochemistry assays can also be done in the near future to determine 
if Rab22B co-localizes with EGFR or EEA1. This presence of Rab22B and EGFR or 
EEA1 in the same membranes would go further to prove that Rab22B and EGFR or 
EEA1 do indeed associate with each other to elicit the phenomenon that was observed. 
 
Therefore, in the light of the above theory that Rab22B may share common 
regulators and effectors with the endocytic Rabs, silencing of Rab22B might indirectly 
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alter the activity of the endosomal Rabs by creating less competition for the common 
regulators and effectors. This could consequently, lead to an alteration to EGFR traffic. 
This possibility, although non-physiological, could become relevant in a pathological 
setting. Considering our finding that Rab22B silencing increases A431 cell proliferation, 
and that aberrant EGFR signaling being a frequent mechanism underlying multiple type 
of human malignancy, alterations of Rab22B levels during events of somatic cell 
mutations could well impinge on EGFR trafficking and signaling in such a way that 







Fig. 3.48: Rab22B co-immunoprecipitates with EEA1 in a GTP-dependent manner in vivo. 
3 μg of antibodies (Rab22B or IgG as negative control) were added to 1 mg of HeLa 
lysate. The antibodies were incubated with the lysate, followed by addition of Protein A 
or G sepharose beads. Beads were then washed and bound proteins eluted with SDS-
PAGE sample buffer, followed by Western immunoblot analysis with respective 
Rab/myc (upper panel) or EEA1 antibody (BD Biosciences: 610457).  
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4 Conclusions and future perspectives 
 
4.1 General conclusions 
 
In this thesis, I report on the characterization and functional studies of a brain-
enriched Rab GTPase, Rab22B. Rab22B was first cloned 12 years ago (Chen et al., 1996). 
However, other than the fact that it is brain-enriched, the brain expression profile, exact 
cellular and sub-cellular localization, and functions have remained uncharacterized. This 
may be in part due to a lack of specific reagent that would specifically recognized 
Rab22B. To this end, I have developed specific antibodies against Rab22B, which does 
not cross react with its close paralogue Rab22A, to help to answer the above questions. 
 
A tissue survey, via Western immunoblot analysis, using specific antibodies 
raised against Rab22B confirms that Rab22B’s protein is indeed brain-enriched. 
Rab22B’s protein is also detected at appreciable levels in spleen and intestine, but 
undetectable in other tissues. Immunohistochemistry analysis revealed that in the 
embryonic brain, Rab22B labeling is found primarily in nestin and RC2-positive fibers of 
the radial glia. In the adult mouse brain, Rab22B is rather specifically expressed in 
GFAP-positive astrocytes, but apparently undetectable in TuJ-positive neurons and 
CNPase-positive oligodendrocytes. These observations were confirmed by similar 
staining of primary astrocytes in culture. 
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Detailed immunocytochemistry analysis performed in HeLa cells revealed that the 
primary membrane localization of Rab22B is at the Golgi/TGN. When the GTP-binding 
mutant, Rab22B SN, is overexpressed, the TGN localization of a dynamic marker, 
TGN46, which cycles between the TGN and the plasma membrane, is disrupted. This 
effect is specific as TGN resident membrane protein such as syntaxin 16, and cis-Golgi 
markers such as GM130 and syntaxin 5, and the TGN/late endosomal marker, mannose 
6-phosphate receptor (M6PR), were not affected. These results demonstrate that Rab22B 
SN affected dynamic TGN traffic. 
 
Rab22B’s apparent TGN localization and its’ ability to disrupt the steady state 
staining pattern of a dynamic TGN marker indicated that it may be involved in trafficking 
in and/or out of the TGN. Further investigations showed that Rab22B is not involved, or 
not essential for retrograde trafficking of some common endocytic cargoes such as the 
endocytic itineraries of transferrin and Shiga B toxin. However, over-expression of the 
Rab22B SN mutant has a discernible inhibitory effect on the exit of an anterograde cargo, 
VSVG, out of the TGN.  
 
Rab22B shares its guanine nucleotide exchange factor, GAPex-5, with Rab5 
(Lodhi et al., 2007). In the brain, GAPex-5 is also apparently enriched in Rab22B-
positive astrocytes. Rab22B silencing inhibited or delayed the trafficking of EGFR, as 
well as Texas-Red conjugated EGF, into the CD63-positive late endosomal compartment, 
as did the silencing of GAPex-5. Affinity pull-down assay and co-immunoprecipitation 
analysis show that Rab22B interacts with EGFR in a GTP-dependent manner. While the 
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silencing of Rab22B did not affect the magnitude of phosphorylation of the signalling 
intermediates downstream of EGFR, ERK1/2, phosphorylation of ERK1/2 appears to 
persist longer in Rab22B depleted cells. This provided an explanation as to why cell 
proliferation rates, monitored over 72 hours, were significantly increased in cells treated 
with Rab22B siRNA as compared to scramble control RNA. 
 
In summary, my work revealed Rab22B as the first Rab GTPase that is 
specifically enriched in the brain astroglia lineage, and that it may play a role in 
regulating both TGN and post-Golgi trafficking. Although Rab22B may not be essential 
for general membrane traffic, it may be important for the trafficking of specific cargoes, 
particularly in cell types in which it is highly expressed. 
 
4.2 Future perspectives and directions 
 
 While the physiological role of Rab22B in radial glia and astrocytes are unknown 
at the moment, it is hoped that the results presented in this thesis would provide sufficient 
groundwork and impetus for future research on this protein. Some interesting issues 
which had arise during the course of my studies on Rab22B, as well as possible future 
investigations, are discussed below. 
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Rab22B, TGN transport and astrocytes 
 
Rab22B’s apparent Golgi/TGN localization (Section 3.3) and the ability to disrupt 
a dynamic TGN marker, TGN46 (Section 3.4), seemed to indicate that it may be involved 
in trafficking in and/or out of the TGN. While the over-expression of the GTP-binding 
mutant, Rab22B SN inhibited the export of anterograde cargo, VSVG, out of the TGN, 
the depletion of Rab22B does not inhibit the export of VSVG out of the TGN (Section 
3.5). This prompted us to conclude that Rab22B may not be essential for this pathway, 
but may function in concert with other proteins which are involved in anterograde 
transport.  
 
On the other hand, an obvious and important question is does Rab22B play 
essential roles in regulating the export of cargoes in the cell type which it is enriched in, 
i.e., astrocytes? Astrocytes had been reported to express the proteins synaptophysin, 
synaptobrevin and Rab3, which are required for exocytosis (Anlauf and Derouiche, 2004). 
Furthermore, in a proteomic analysis reported by Lafon-Cazal et al., (2003), astrocytes 
were confirmed to be able to secrete proteins such as complement C3 and apolipoprotein 
E in the classical vesicular secretion pathway. Other reports had also indicated that 
astrocytes can secrete growth factors such ciliary neurotrophic factor (CNTF) to promote 
astrocytic differentiation from neural progenitors (Chang et al., 2003), fibroblast growth 
factor (FGF) (Ito et al., 2005) and brain-derived neurotrophic factor (BDNF) (Young et 
al., 2003) to promote healing during injury and thrombospondins to induce 
synaptogenesis (Christopherson et al., 2005).  
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 In the light of the above, it would be interesting to determine if Rab22B does 
regulate the exocytosis of any of these proteins in astrocytes, as well as the spatial and 
temporal controls that are required for the cells to control the expression of Rab22B. We 
have not been able to obtain astrocytic cell lines that are useful for these analyses, and 
our earlier attempts at immortalizing primary astrocytes with exogenous telomerase 
expression had not been successful. 
 
Does Rab22B regulate EGFR’s  trafficking and signaling  during  gliogenesis and 
astroglia differentiation? 
 
My results show that Rab22B protein is lower in embryonic stages E14-16, 
coinciding with the beginning of gliogenesis, and Rab22B silencing delays EGFR’s 
trafficking to the lysosomes. Previous studies had reported that the slowing down of 
EGFR degradation will result in continuous signaling from EGFR, thus, resulting in a 
sustained ERK and p38 signaling, and consequently, hyperactivation of nuclear targets 
such as Elk-1 (Taub et al., 2007), which had been implicated in cell growth, 
differentiation and development. Previous reports had also link EGFR’s signaling to cell 
differentiation in the central nervous system (Sibilia et al., 1998; Dumstrei et al., 1998; 
Fallon et al., 2000). In particular, the levels of EGFR expressed by progenitor cells, 
especially in the cortex, may contribute to the timing of their maturation and choice of 
response to other environmental signals (Burrows et al., 1997). Coincidentally, the peak 
of EGFR expression also coincides with the peak of gliogenesis (Burrows et al., 1997). 
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Also, in EGFR-/- mice, there had been reports of abnormal astrocyte development 
(Kornblum et al., 1998; Sibilia et al., 1998).  
 
In the contexts above, it would be of interest to evaluate if Rab22B is critical or in 
itself, could induce astroglia differentiation and if a change in Rab22B’s protein levels 
would affect EGFR’s trafficking during the process of gliogenesis. Such investigations 
would entail the use of neural progenitor cells (NPC). The effect of over-expressing 
Rab22B, its’ dominant-negative mutant or depletion by siRNA on the maturation of these 
NPCs can be examined in the near future.  
 
Would pathogenic alterations of Rab22B levels affect EGFR trafficking and 
promote cellular transformation and oncogenesis? 
 
 My results indicate that Rab22B can associate with EGFR and influence its 
trafficking itinerary. In Section 3.6, it was shown that Rab22B can also interact with 
EEA1, an early endosomal protein (Fig. 3.48), in a GTP-dependent manner. EEA1 is also 
an effector for endosomal Rabs, Rab5 and Rab22A (Christoforidis et al., 1999; Kauppi et 
al., 2002), which are all Rabs involved in regulating various aspects of endocytosis.  
GAPex-5, a GEF for Rab5, is also a GEF for Rab22B (Lodhi et al., 2007). Other than a 
direct association with EGFR, Rab22B could thus also affect other Rab proteins that 
regulate EGFR trafficking and signaling via the sharing of effectors as well as regulatory 
factors.  It is therefore conceivable that pathological changes in Rab22B expression levels 
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might directly or indirectly alter the EGFR trafficking and signaling, and perhaps 
(unsubstantiated) that of other growth factor receptors.  
 
EGFR signaling is often up-regulated in cancers and tumors due to defects in its 
downregulation or constitutive activation (El-Jawahri et al., 2008; Freeman et al., 2008; 
Miyanaga et al., 2008; Nieto et al, 2007). Interestingly, it has been recently shown that 
Rab22B is up-regulated in samples from breast cancer patients with the worst prognosis 
(Kotzsch et al., 2008), Although this is apparently at odds with my finding that Rab22B 
silencing increase A431 cell proliferation, it may  reflect a compensatory response by the 
cells to downregulate growth factor signaling. In view of the above, it may be of clinical 
importance to further determine if changes in Rab22B expression are associated with 
cancer.  
 
 Is Rab22B crucial for CNS development? 
 
 Finally, is Rab22B crucial for the development of the CNS? In EGFR-/- mouse, 
abnormal astroycte development and ectopic neurons were noted (Sibilia et al., 1998). If 
Rab22B does influence EGFR trafficking and signaling, what would the phenotype of a 
Rab22B-/- mouse (assuming that Rab22B deletion does not result in embryonic lethality), 
or one with a conditional knock-out of Rab22B only in astrocytes be?  At the moment, 
one may speculate that there would be abnormal astrocyte development. Cells derived 
from a Rab22B conditional knock-out mouse would be most useful for the dissection of 
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Rab22b regulated membrane traffic pathways. This and other directions discussed above 
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Fig. A1: Rab40C WT and its’ mutants disrupt TGN46 staining. Myc-tagged Rab40C WT 
and its’ mutants were over-expressed in HeLa cells. Cells were fixed for 
immunofluorescence analysis with myc and TGN46 antibodies, followed FITC-





Fig. A2: GST-Rab40C can pull down EEA1 in a GTP-dependent manner. 20μg of GST or 
GST::Rab40C recombinant protein beads were added to 1 mg of HeLa lysate, and 
incubated for a few hours. Beads were then washed and bound proteins eluted with SDS-




Fig. A3: Over-expression Rab40C of affects the transport of Tf-FITC. Myc-tagged 
Rab40C WT and its’ mutants were over-expressed in HeLa cells. Following transfection 
(after 16-18 hours), the cells were subjected to a 18
o
C incubation to internalize 
transferrin-FITC and a further incubation at 37
o
C for 10 minutes. Cells were then fixed 
for immunofluorescence analysis with myc antibodies, followed by TxR-conjugated 
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 The expression profile and functions of the brain-enriched Rab22B/Rab31 small 
GTPase had remained uncharacterized. Using specific antibodies against Rab22B, we 
found the protein to be exceptionally enriched in nestin and RC2-positive radial glia of 
embryonic mouse brain. In the adult brain, Rab22B is rather specifically expressed in 
glial fibrillary acidic protein (GFAP)-positive mature astrocytes, but is not clearly 
detectable in either CNPase-positive mature oligodendrocytes or III-tubulin-positive 
neurons. In probing for specific functions of Rab22B, we found that Rab22B silencing in 
A431 cells resulted in abnormal trafficking of the epidermal growth factor receptor 
(EGFR) as well as Texas-Red-labeled EGF. Affinity pull-down assays and co-
immunoprecipitation analysis indicated that Rab22b could associate with EGFR in a 
GTP-dependent manner. Rab22B is thus a Rab protein specifically expressed in the 
astrogolia lineage and may have a role in regulating EGFR trafficking. 
 
 
 
 
 
 
 
  
 
 
